Optimized high yield synthetic plasmids

ABSTRACT

One aspect of the current invention is an optimized synthetic mammalian expression plasmid with a mutated origin of replication (e.g. “mut” family of plasmids). This new plasmid comprises a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5′ untranslated region (“UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, a selectable marker gene sequence, and an improved origin of replication. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.

RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent Application Ser. No. 60/647,170 titled “Optimized High Yield Synthetic Plasmids,” filed on Jan. 26, 2005, having Draghia-Akli et al., listed as inventors, the entire content of which is hereby incorporated by reference.

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH

No federal funds were used in the development of the present invention.

BACKGROUND

One aspect of the current invention is an optimized high yield nucleic acid delivery vehicle, or synthetic expression plasmid. The synthetic expression plasmid of this invention has reduced components, and has been optimized to increase yield. In addition to a mammalian gene of interest, a typical nucleic acid delivery vehicle or synthetic expression plasmid contains many structural elements necessary for the in vitro amplification of the plasmid in a bacterial host. By restricting the plasmid backbone to essential bacterial structural elements (e.g. bacterial antibiotic resistance gene and origin of replication) one can eliminate detrimental sequences, but not affect the final gene product. By introducing targeted substitutions in the bacterial origin of replication, one can increase plasmid yield and decrease fermentation time, thus increasing productivity. The current invention involves a “synthetic plasmid backbone” that provides a small backbone with an improved origin of replication (“mut 8”), which is useful for plasmid supplementation therapy in mammals.

A plasmid based mammalian expression system is minimally composed of a plasmid backbone, and a nucleic acid sequence encoding a therapeutic expression product under the transcriptional regulation of a promoter, and followed by a 3′UTR and/or polyadenylation signal. A plasmid backbone typically contains elements necessary for the specific growth of only the bacteria that are transformed with the proper plasmid: (1) a bacterial origin of replication, and (2) a selection marker, typically a bacterial antibiotic resistance gene. However, there are plasmids, called mini-circles, that lack both the antibiotic resistance gene and the origin of replication (Darquet et al., 1997; Darquet et al., 1999; Soubrier et al., 1999). Production and purification of mini-circles is complex and extremely costly, and thus impractical for therapeutic applications in large animals and humans.

The use of in vitro amplified expression plasmid DNA (i.e. non-viral expression systems or plasmids) avoids the risks associated with viral vectors (Frederickson et al., 2003). The non-viral expression systems products generally have low toxicity due to the use of “species-specific” components, or components that are not expressed in eukaryotic cells, which minimizes the risks of immunogenicity generally associated with viral vectors. One aspect of the current invention is a new, versatile, optimized high yield plasmid-based mammalian expression system that will reduce the risk of adverse effects associated with prokaryotic nucleic acid sequences in mammalian hosts, while facilitating its in vitro production. In addition, this new plasmid will constitute the base of a species-specific library of plasmids for expression of hormones or other proteins for agricultural, companion animal and human applications.

The nucleotide sequence of the bacterial gene products can adversely affect a mammalian host receiving plasmid DNA. For example, it is desirable to avoid CpG sequences, as these sequences have been shown to cause a recipient host to have an immune response targeted against the plasmids (Manders and Thomas, 2000; Scheule, 2000), as well as possible gene silencing (Shi et al., 2002; Shiraishi et al., 2002). Thus, when properly designing and generating DNA coding regions of any expressed genes one could avoid the “cg” sequence, without changing the amino acid sequence. This process, called “optimization” was used to generate the plasmids described in the present application. Another aspect of the current invention involves the removal of unnecessary backbone DNA sequences that were shown to have no functionality in the new plasmid context. As a result of removal of unnecessary DNA sequences, a new plasmid backbone (“pAV9001”) with unique cloning sites was constructed, which will be useful for plasmid-mediated gene supplementation.

RNA II is the primer for replication of ColE1-derived plasmids and it is inhibited by RNA I (Dasgupta et al., 1987; Gayle, III et al., 1986). Increasing the RNA II to RNA I ratio should increase the frequency of DNA replication initiation events, which should yield higher plasmid copy number. The danger is the production of levels of RNA II that are so elevated that they would lead to “runaway” plasmid replication. Thus, strict control of the relative potency of these sequences is necessary. In another embodiment of this invention, new improved RNA II sites were created. Plasmids containing these new sequences have decreased fermentation time to optimum concentration and result in high plasmid yields.

Two conserved regions about 35 and 10 base pairs (bp) upstream from the transcription start (−35 and −10 regions, respectively) were identified by comparison of numerous promoters (Harley and Reynolds, 1987). Extensive compilations and comparison of promoters of genes of E. coli and it plasmids supported and extended the concept of a “consensus” promoter sequence: a −35 (TTGACA) and −10 (TATAAT) region separated by 17 bp with transcription initiation at a purine about 7 bp downstream from the 3′end of the −10 region (Ross et al., 1998). While the −35 and −10 regions show the greatest conservation across promoters and are also the sites of nearly all mutations which affect transcriptional strength, other bases flanking the −35 and −10 regions, in addition to the start point also occur at greater than random frequencies and sometimes affect promoter activity (Bujard et al., 1983; Deuschle et al., 1986; Kammerer et al., 1986). In addition, variations in spacing between the −35 and −10 regions play a role in promoter strength.

Point mutations in the RNA II promoter: A mutation described in (Bert et al., 2000), alters the −10 element in the RNA II promoter from TAATCT to TAATAT in a ColE1-derived plasmid named pXPM. The mutated sequence is a closer match to the consensus −10 element described above, and was therefore predicted to increase the rate of RNA II transcription. Nevertheless, the effect of mutations in the particular context of each plasmid is highly unpredictable. We modified a plasmid with a pUC origin of replication which requires special fermentation condition, and already contains a mutation of a C to a T (located at position +112 of RNA II in the region of stem/loop IV that hybridizes to 5′ end of RNA I) that increases plasmid copy number (Lahijani et al., 1996; Lin-Chao et al., 1992). The effectiveness and results of combination of mutations is unpredictable, and can be assessed only by measuring plasmid yield, after the sequence has been synthetically generated.

There are several different approaches that can be utilized for the treatment of chronic conditions, such as cancer, arthritis, renal failure or immune dysfunction. Effective treatment may require the presence of therapeutic agents for extended periods of time. In the case of proteins, this is problematic. Gene therapeutic approaches may offer a solution to this problem. Experimental studies have confirmed the feasibility, efficacy and safety of plasmid-mediated gene supplementation for the treatment of chronic conditions.

Direct plasmid DNA gene transfer is currently the basis of many emerging nucleic acid therapy strategies and does not require viral components or lipid particles (Aihara and Miyazaki, 1998; Muramatsu et al., 2001). Skeletal muscle is target tissue, because muscle fiber has a long life span and can be transduced by circular DNA plasmids that are expressed in immunocompetent hosts (Davis et al., 1993; Tripathy et al., 1996). Plasmid DNA constructs are attractive candidates for direct therapy into the subjects skeletal muscle because the constructs are well-defined entities that are biochemically stable and have been used successfully for many years (Acsadi et al., 1991; Wolff et al., 1990). The relatively low expression levels of an encoded product that are achieved after direct plasmid DNA injection are sometimes sufficient to indicate bio-activity of secreted peptides (Danko and Wolff, 1994; Tsurumi et al., 1996). Previous reports demonstrated that human GHRH cDNA could be delivered to muscle by an injectable myogenic expression vector in mice where it transiently stimulated GH secretion to a modest extent over a period of two weeks (Draghia-Akli et al., 1997).

Efforts have been made to enhance the delivery of plasmid DNA to cells by physical means including electroporation, sonoporation, and pressure. Although not wanting to be bound by theory, the administration of a nucleic acid construct by electroporation involves the application of a pulsed electric field to create transient pores in the cellular membrane without causing permanent damage to the cell, which allows exogenous molecules to enter the cell (Smith and Nordstrom, 2000). By adjusting the electrical pulse generated by an electroporetic system, nucleic acid molecules can travel through passageways or pores in the cell that are created during the procedure. U.S. Pat. No. 5,704,908 titled “Electroporation and iontophoresis catheter with porous balloon,” issued on Jan. 6, 1998 with Hofmann et al., listed as inventors describes an electroporation apparatus for delivering molecules to cells at a selected location within a cavity in the body of a patient. Similar pulse voltage injection devices are also described in: U.S. Pat. No. 5,702,359 titled “Needle electrodes for mediated delivery of drugs and genes,” issued on Dec. 30, 1997, with Hofmann, et al., listed as inventors; U.S. Pat. No. 5,439,440 titled “Electroporation system with voltage control feedback for clinical applications,” issued on Aug. 8, 1995 with Hofmann listed as inventor; PCT application WO/96/12520 titled “Electroporetic Gene and Drug Therapy by Induced Electric Fields,” published on May 5, 1996 with Hofmann et al., listed as inventors; PCT application WO/96/12006 titled “Flow Through Electroporation Apparatus and Method,” published on Apr. 25, 1996 with Hofmann et al., listed as inventors; PCT application WO/95/19805 titled “Electroporation and Iontophoresis Apparatus and Method For insertion of Drugs and genes into Cells,” published on Jul. 27, 1995 with Hofmann listed as inventor; and PCT application WO/97/07826 titled “In Vivo Electroporation of Cells,” published on Mar. 6, 1997, with Nicolau et al., listed as inventors, the entire content of each of the above listed references is hereby incorporated by reference.

Recently, significant progress to enhance plasmid delivery in vivo and subsequently to achieve physiological levels of a secreted protein was obtained using the electroporation technique. Electroporation has been used very successfully to transfect tumor cells after injection of plasmid (Lucas et al., 2002; Matsubara et al., 2001)) or to deliver the anti-tumor drug bleomycin to cutaneous and subcutaneous tumors in humans (Gehl et al., 1998; Heller et al., 1996). Electroporation also has been extensively used in mice (Lesbordes et al., 2002; Lucas et al., 2001; Vilquin et al., 2001), rats (Terada et al., 2001; Yasui et al., 2001) and dogs (Fewell et al., 2001) to deliver therapeutic genes that encode for a variety of hormones, cytokines or enzymes. Previous studies using GHRH showed that plasmid therapy with electroporation is scalable and represents a promising approach to induce production and regulated secretion of proteins in large animals and humans (Draghia-Akli et al., 1999; Draghia-Akli et al., 2002c). Electroporation also has been extensively used in rodents and other small animals (Bettan et al., 2000; Yin and Tang, 2001). Intramuscular injection of plasmid followed by electroporation has been used successfully in ruminants for vaccination purposes (Babiuk et al., 2003; Tollefsen et al., 2003). It has been observed that the electrode configuration affects the electric field distribution, and subsequent results (Gehl et al., 1999; Miklavcic et al., 1998). Although not wanting to be bound by theory, needle electrodes give consistently better results than external caliper electrodes in a large animal model.

The ability of electroporation to enhance plasmid uptake into the skeletal muscle has been well documented. Similarly, plasmids formulated with poly-L-glutamate (“PLG”) or polyvinylpyrrolidone (“PVP”) were observed to have an increase in plasmid transfection, which consequently increased the expression of a desired transgene. For example, plasmids formulated with PLG or PVP were observed to increase gene expression to up to 10 fold in the skeletal muscle of mice, rats, and dogs (Fewell et al., 2001; Mumper et al., 1998). Although not wanting to be bound by theory, the anionic polymer sodium PLG enhances plasmid uptake at low plasmid concentrations and reduces any possible tissue damage caused by the procedure. PLG is a stable compound and it is resistant to relatively high temperatures (Dolnik et al., 1993). PLG has been used to increase stability of anti-cancer drugs (Li et al., 2000) and as “glue” to close wounds or to prevent bleeding from tissues during wound and tissue repair (Otani et al., 1996; Otani et al., 1998). PLG has been used to increase stability in vaccine preparations (Matsuo et al., 1994) without increasing their immunogenicity. PLG also has been used as an anti-toxin after antigen inhalation or exposure to ozone (Fryer and Jacoby, 1993).

Although not wanting to be bound by theory, PLG increases the transfection of the plasmid during the electroporation process, not only by stabilizing the plasmid DNA and facilitating the intracellular transport through the membrane pores, but also through an active mechanism. For example, positively charged surface proteins on the cells could complex the negatively charged PLG linked to plasmid DNA through protein-protein interactions. When an electric field is applied, the surface proteins reverse direction and actively internalize the DNA molecules, a process that substantially increases the transfection efficiency. Furthermore, PLG will prevent the muscle damage associated with in vivo plasmid delivery (Draghia-Akli et al., 2002b) and will increase plasmid stability in vitro prior to injection. There are studies directed to electroporation of eukaryotic cells with linear DNA (McNally et al., 1988; Neumann et al., 1982) (Toneguzzo et al., 1988) (Aratani et al., 1992; Naim et al., 1993; Xie and Tsong, 1993; Yorifuji and Mikawa, 1990), but these examples illustrate transfection into cell suspensions, cell cultures, and the like, and such transfected cells are not present in a somatic tissue.

U.S. Pat. No. 4,956,288 is directed to methods for preparing recombinant host cells containing high copy number of a foreign DNA by electroporating a population of cells in the presence of the foreign DNA, culturing the cells, and killing the cells having a low copy number of the foreign DNA.

Although not wanting to be bound by theory, a GHRH cDNA can be delivered to muscle of mice and humans by an injectable myogenic expression vector where it can transiently stimulate GH secretion over a period of two weeks (Draghia-Akli et al., 1997). This injectable vector system was optimized by incorporating a powerful synthetic muscle promoter (Li et al., 1999) coupled with a novel protease-resistant GHRH molecule with a substantially longer half-life and greater GH secretory activity (pSP-HV-GHRH) (Draghia-Akli et al., 1999). Highly efficient electroporation technology was optimized to deliver the nucleic acid construct to the skeletal muscle of an animal (Draghia-Akli et al., 2002b). Using a skillful combination of vector design and electric pulses plasmid delivery method, the inventors were able to show increased growth and favorably modified body composition in pigs (Draghia-Akli et al., 1999; Draghia-Akli et al., 2003) and rodents (Draghia-Akli et al., 2002c), and improved immune surveillance in dairy cattle (Brown et al., 2004). The modified GHRH nucleic acid constructs increased red blood cell production in companion animals with cancer and cancer treatment-associated anemia (Draghia-Akli et al., 2002a).

Administering novel GHRH analog proteins (U.S. Pat. Nos. 5,847,066; 5,846,936; 5,792,747; 5,776,901; 5,696,089; 5,486,505; 5,137,872; 5,084,442, 5,036,045; 5,023,322; 4,839,344; 4,410,512, RE33,699) or synthetic or naturally occurring peptide fragments of GHRH (U.S. Pat. Nos. 4,833,166; 4,228,158; 4,228,156; 4,226,857; 4,224,316; 4,223,021; 4,223,020; 4,223,019) for the purpose of increasing release of growth hormone have been reported. A GHRH analog containing the following mutations have been reported (U.S. Pat. No. 5,846,936): Tyr at position 1 to His; Ala at position 2 to Val, Leu, or others; Asn at position 8 to Gln, Ser, or Thr; Gly at position 15 to Ala or Leu; Met at position 27 to Nle or Leu; and Ser at position 28 to Asn. The GHRH analog is the subject of U.S. Pat. No. 6,551,996 titled “Super-active porcine growth hormone releasing hormone analog,” issued on Apr. 22, 2003 with Schwartz, et al., listed as inventors (“the '996 patent”), which teaches application of a GHRH analog containing mutations that improve the ability to elicit the release of growth hormone. In addition, the '996 patent application relates to the treatment of growth deficiencies; the improvement of growth performance; the stimulation of production of growth hormone in an animal at a greater level than that associated with normal growth; and the enhancement of growth utilizing the administration of growth hormone releasing hormone analog and is herein incorporated by reference.

In summary, prior art has shown that it is possible to create new plasmids in a limited capacity utilizing existent plasmids or fragments from previously produced plasmids, but these techniques, and the resultant plasmids have some significant drawbacks: numerous CpG islands that can inhibit and reduce expression after treatment in vivo, large plasmid backbones that can accommodate relatively small transgenes, numerous bacterial elements with unknown function in eukaryotic cells, multiple cloning site regions with unknown effect on expression and replication, etc. It has also been taught that nucleic acid expression plasmids that encode recombinant proteins are viable solutions to the problems of frequent injections and high cost of traditional recombinant therapy. However, the nucleic acid expression plasmids also have some drawbacks when injected into a mammalian host. The synthetic plasmids of this invention have reduced components, and have been codon optimized to increase efficacy, and reduce adverse reactions in vivo. The introduction of point mutations in to the encoded recombinant proteins was a significant step forward in producing proteins that are more stable in vivo than the wild-type counterparts. Since there is a need in the art to expanded treatments for subjects with a disease by utilizing nucleic acid expression constructs that are delivered into a subject and express stable therapeutic proteins in vivo, the combination of codon optimization of an encoded therapeutic mammalian gene in an optimized plasmid backbone will further enhance the art of plasmid-mediated gene supplementation. Furthermore, the creation of new, improved optimized plasmids allow for better and more efficient production, with lower manufacturing costs and less time per round of production/purification.

SUMMARY

One aspect of the current invention is an optimized synthetic mammalian expression plasmid with modified origin of replication (e.g. “mut 8”). This new plasmid comprises a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5′ untranslated region (“5′UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a polyadenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, and an improved origin of replication. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.

In preferred embodiments, the synthetic mammalian expression plasmid comprises a pUC-18 prokaryotic origin of replication sequence. However, the origin of replication may also comprise an autonomously replication sequence (“ARS”), or modifications that may improve plasmid yield and time of fermentation. Additionally, the codon-optimized plasmid backbone comprises at least one optimized CpG codon. In a preferred embodiment, the polyadenylation signal (“polyA”) comprises a human growth hormone (“hGH”) poly(A) signal, and a hGH 5′ untranslated region (“5′UTR”). The codon-optimized mammalian therapeutic gene sequence comprises a sequence that encodes a species-specific or modified growth hormone releasing hormone (“GHRH”). In preferred embodiments, the codon-optimized sequence comprises human, porcine, mouse, rat, bovine, ovine, and chicken GHRH, or their analogs.

Another aspect of the current invention is a method for plasmid mediated gene supplementation that comprises delivering a codon-optimized synthetic mammalian expression plasmid into a subject. The codon-optimized synthetic mammalian expression plasmid encodes a growth hormone releasing hormone (“GHRH”) or functional biological equivalent in the subject. The method of delivering the codon-optimized synthetic mammalian expression plasmid into the cells of the subject is via direct plasmid injection into the target tissue or organ followed by electroporation. In a preferred embodiment, the cells of the subject can be somatic cells, stem cells, or germ cells. The codon-optimized synthetic mammalian expression plasmids consisting of SEQ ID NO.: 2, SEQ ID NO.: 12, SEQ ID NO.: 13, SEQ ID NO.: 14, SEQ ID NO.: 15 have been contemplated by the inventors. The encoded GHRH is a biologically active polypeptide; and the encoded functional biological equivalent of GHRH is a polypeptide that has been engineered to contain a distinct amino acid sequence while simultaneously having similar or improved biologically activity when compared to the GHRH polypeptide. One result of expressing the encoded GHRH or functional biological equivalent thereof in a subject is the facilitation of growth hormone (“GH”) secretion in the subject.

BRIEF DESCRIPTION OF FIGURES

FIG. 1 shows a general map of a plasmid construct (pAV0125, this plasmid contains the porcine modified HV-GHRH sequence) used prior construction of an optimized synthetic plasmid of the current invention;

FIG. 2 shows a general map of a synthetic plasmid construct “pAV0201”; this construct contains the porcine modified GHRH called HV-GHRH of the current invention, which contains codon-optimization;

FIG. 3 shows a general map of a synthetic plasmid construct “pAV0224”; this construct contains the porcine modified GHRH called HV-GHRH of the current invention, which contains codon-optimization, and improved origin of replication;

FIG. 4 shows a general map of a synthetic plasmid construct “pAV0225”; this construct contains the porcine wild-type GHRH called wt-GHRH of the current invention, which contains codon-optimization, and improved origin of replication;

FIG. 5 shows a general map of a synthetic plasmid construct “pAV0237”; this construct contains the porcine wild-type GHRH called wt-GHRH of the current invention, which contains codon-optimization, and improved origin of replication, including deletions in the 3′end of “ori”;

FIG. 6 shows a general map of a synthetic plasmid construct “pAV0242”; this construct contains the porcine wild-type GHRH called wt-GHRH of the current invention, which contains codon-optimization, and improved origin of replication, including deletions in the 3′end of “ori” and in regions located between the eukaryotic expression cassette and the kanamycin resistance gene;

FIG. 7 shows the number of colonies obtained after transformation of origin of replication mutants: mut1, mut 2, mut 3, mut 8 and mut 9, compared to the number of colonies obtained after transformation of the newly produced plasmid “pAV0242”.

FIG. 8 shows the average optic density (OD) readings obtained during fermentation of plasmids containing the origin of replication mutants: mut1, mut 2, mut 3, mut 8 and mut 9, compared to the optic density (OD) readings obtained during fermentation of the newly produced plasmid “pAV0242”.

FIG. 9 shows the average midi-prep plasmid yields obtained after fermentation of plasmids containing the origin of replication mutants: mut1, mut 2, mut 3, mut 8 and mut 9, compared average midi-prep plasmid yields obtained after fermentation of the newly produced plasmid “pAV0242”.

FIG. 10 shows the average giga-prep plasmid yields obtained after fermentation of plasmids containing the origin of replication mutants: mut1, mut 2, mut 3, mut 8 and mut 9, compared average giga-prep plasmid yields obtained after fermentation of the newly produced plasmid “pAV0242”.

FIG. 11 shows publicly available databases references for optimized codons.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Terms: It will be readily apparent to one skilled in the art that various substitutions and modifications may be made in the invention disclosed herein without departing from the scope and spirit of the invention.

The term “a” or “an” as used herein in the specification may mean one or more. As used herein in the claim(s), when used in conjunction with the word “comprising”, the words “a” or “an” may mean one or more than one. As used herein “another” may mean at least a second or more.

The term “analog” as used herein includes any mutant of GHRH, or synthetic or naturally occurring peptide fragments of GHRH.

The term “cassette” as used herein is defined as one or more transgene expression sequences.

The term “cell-transfecting pulse” as used herein is defined as a transmission of a force which results in transfection of a vector, such as a linear DNA fragment, into a cell. In some embodiments, the force is from electricity, as in electroporation, or the force is from vascular pressure.

The term “coding region” as used herein refers to any portion of the DNA sequence that is transcribed into messenger RNA (mRNA) and then translated into a sequence of amino acids characteristic of a specific polypeptide.

The term “codon” as used herein refers to any group of three consecutive nucleotide bases in a given messenger RNA molecule, or coding strand of DNA that specifies a particular amino-acid, a starting or stopping signal for translation. The term codon also refers to base triplets in a DNA strand.

“Conservatively modified variations” of a particular nucleic acid sequence refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given polypeptide. For instance, the codons CGU, CGC, CGA, CGG, AGA, and AGG all encode the amino acid arginine. Thus, at every position where an arginine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of “conservatively modified variations.” Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine) can be modified to yield a functionally identical molecule by standard techniques. Accordingly, each “silent variation” of a nucleic acid which encodes a polypeptide is implicit in each described sequence. Furthermore, one of skill will recognize that individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (typically less than 15%, more typically less than 5%, and even more typically less than 1%) in an encoded sequence are “conservatively modified variations” where the alterations result in the substitution of an amino acid with a chemically similar amino acid. Conservative amino acid substitutions providing functionally similar amino acids are well known in the art. The following six groups each contain amino acids that are conservative substitutions for one another:

1) Alanine (A), Serine (S), Threonine (T);

2) Aspartic acid (D), Glutamic acid (E);

3) Asparagine (N), Glutamine (Q);

4) Arginine (R), Lysine (K);

5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and

6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

The term “complementary” means that one nucleic acid molecule has the sequence of the binding partner of another nucleic acid molecule. Thus, the sequence 5′-ATGC-3′ is complementary to the sequence 5′-GCAT-3′.

The term “codon” as used herein refers to any group of three consecutive nucleotide bases in a given messenger RNA molecule, or coding strand of DNA that specifies a particular amino-acid, or a starting or stopping signal for translation. The term codon also refers to base triplets in a DNA strand.

The term “coding region” as used herein refers to any portion of the DNA sequence that is transcribed into messenger RNA (mRNA) and then translated into a sequence of amino acids characteristic of a specific polypeptide.

The term “delivery” as used herein is defined as a means of introducing a material into a subject, a cell or any recipient, by means of chemical or biological process, injection, mixing, electroporation, sonoporation, or combination thereof, either under or without pressure.

The term “electroporation” as used herein refers to a method that utilized electric pulses to deliver a nucleic acid sequence into cells.

The terms “electrical pulse” and “electroporation” as used herein refer to the administration of an electrical current to a tissue or cell for the purpose of taking up a nucleic acid molecule into a cell. A skilled artisan recognizes that these terms are associated with the terms “pulsed electric field” “pulsed current device” and “pulse voltage device.” A skilled artisan recognizes that the amount and duration of the electrical pulse is dependent on the tissue, size, and overall health of the recipient subject, and furthermore knows how to determine such parameters empirically.

The term “encoded GHRH” as used herein is a biologically active polypeptide.

The term “functional biological equivalent” of GHRH as used herein is a polypeptide that has a distinct amino acid sequence from a wild type GHRH polypeptide while simultaneously having similar or improved biological activity when compared to the GHRH polypeptide. The functional biological equivalent may be naturally occurring or it may be modified by an individual. A skilled artisan recognizes that the similar or improved biological activity as used herein refers to facilitating and/or releasing growth hormone or other pituitary hormones. A skilled artisan recognizes that in some embodiments the encoded functional biological equivalent of GHRH is a polypeptide that has been engineered to contain a distinct amino acid sequence while simultaneously having similar or improved biological activity when compared to the GHRH polypeptide. Methods known in the art to engineer such a sequence include site-directed mutagenesis.

The term “growth hormone” (“GH”) as used herein is defined as a hormone that relates to growth and acts as a chemical messenger to exert its action on a target cell. In a specific embodiment, the growth hormone is released by the action of growth hormone releasing hormone.

The term “growth hormone releasing hormone” (“GHRH”) as used herein is defined as a hormone that facilitates or stimulates release of growth hormone and in a lesser extent other pituitary hormones, as prolactin.

The term “heterologous nucleic acid sequence” as used herein is defined as a DNA sequence consisting of differing regulatory and expression elements.

The term “identical” in the context of two nucleic acid or polypeptide sequences refers to the residues in the two sequences which are the same when aligned for maximum correspondence. When percentage of sequence identity is used in reference to proteins or peptides it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acids residues are substituted for other amino acid residues with similar chemical properties (e.g. charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a fill mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., according to known algorithm. See, e.g., Meyers and Miller, Computer Applic. Biol. Sci., 4: 11-17 (1988); Smith and Waterman (1981) Adv. Appl. Math. 2: 482; Needleman and Wunsch (1970) J. Mol. Biol. 48: 443; Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85: 2444; Higgins and Sharp (1988) Gene, 73: 237-244 and Higgins and Sharp (1989) CABIOS 5: 151-153; Corpet, et al. (1988) Nucleic Acids Research 16, 10881-90; Huang, et al. (1992) Computer Applications in the Biosciences 8, 155-65, and Pearson, et al. (1994) Methods in Molecular Biology 24, 307-31. Alignment is also often performed by inspection and manual alignment.

The term “isolated” as used herein refers to synthetic or recombinant preparation of molecules in a purified, or concentrated, or both, form, substantially free from undesirable properties.

The term “non-optimized codon” as used herein refers to a codon that does not have a match codon frequency in target and host organisms. The non-optimized codons of this invention were determined using Aptagen's Gene Forge® codon optimization and custom gene synthesis platform (Aptagen, Inc., 2190 Fox Mill Rd. Suite 300, Herndon, Va. 20171). Other publicly available databases for optimized codons are available and will work equally as well, which is indicated in FIG. 11.

The term “nucleic acid expression construct” as used herein refers to any type of an isolated genetic construct comprising a nucleic acid coding for a RNA capable of being transcribed. The term “expression vector” can also be used interchangeably herein. In specific embodiments, the isolated nucleic acid expression construct comprises: a promoter; a nucleotide sequence of interest; and a 3′ untranslated region; wherein the promoter, the nucleotide sequence of interest, and the 3′ untranslated region are operatively linked; and in vivo expression of the nucleotide sequence of interest is regulated by the promoter. The term “DNA fragment” as used herein refers to a substantially double stranded DNA molecule. Although the fragment may be generated by any standard molecular biology means known in the art, in some embodiments the DNA fragment or expression construct is generated by restriction digestion of a parent DNA molecule. The terms “expression vector,” “expression cassette,” or “expression plasmid” can also be used interchangeably. Although the parent molecule may be any standard molecular biology DNA reagent, in some embodiments the parent DNA molecule is a plasmid.

The term “operatively linked” as used herein refers to elements or structures in a nucleic acid sequence that are linked by operative ability and not physical location. The elements or structures are capable of, or characterized by accomplishing a desired operation. It is recognized by one of ordinary skill in the art that it is not necessary for elements or structures in a nucleic acid sequence to be in a tandem or adjacent order to be operatively linked.

The term “optimized codon” as used herein refers to a codon that has increased codon frequency in target and host organisms, but does not alter the amino acid sequence of the original translated protein. The optimized codons of this invention were determined using Aptagen's Gene Forge® codon optimization and custom gene synthesis platform (Aptagen, Inc., 2190 Fox Mill Rd. Suite 300, Herndon, Va. 20171). Other publicly available databases for optimized codons are available and will work equally as well, which is indicated in FIG. 11.

The term “optimized nucleic acid delivery vehicle” as used herein refers to any vector that delivers a nucleic acid into a cell or organism wherein at least one of the codons has been optimized for expression in a host organism. The term “synthetic expression plasmid” can also be used interchangeably with the term optimized nucleic acid delivery vehicle.

The term “plasmid” as used herein refers generally to a construction comprised of extra-chromosomal genetic material, usually of a circular duplex of DNA that can replicate independently of chromosomal DNA. Plasmids, or fragments thereof, may be used as vectors. Plasmids are double-stranded DNA molecule that occur or are derived from bacteria and (rarely) other microorganisms. However, mitochondrial and chloroplast DNA, yeast killer and other cases are commonly excluded.

The term “plasmid backbone” as used herein refers to a sequence of DNA that typically contains a bacterial origin of replication, and a bacterial antibiotic selection gene, which are necessary for the specific growth of only the bacteria that are transformed with the proper plasmid. However, there are plasmids, called mini-circles, that lack both the antibiotic resistance gene and the origin of replication (Darquet et al., 1997; Darquet et al., 1999; Soubrier et al., 1999). The use of in vitro amplified expression plasmid DNA (i.e. non-viral expression systems) avoids the risks associated with viral vectors. The non-viral expression systems products generally have low toxicity due to the use of “species-specific” components for gene delivery, which minimizes the risks of immunogenicity generally associated with viral vectors. One aspect of the current invention is that the plasmid backbone does not contain viral nucleotide sequences, and it is small.

The term “plasmid mediated gene supplementation” as used herein refers a method to allow a subject to have prolonged exposure to a therapeutic range of a therapeutic protein by utilizing a nucleic acid-expression construct in vivo.

The term “poly-L-glutamate (“PLG”)” as used herein refers to a biodegradable polymer of L-glutamic acid that is suitable for use as a vector or adjuvant for DNA transfer into cells with or without electroporation.

The term “promoter” as used herein refers to a sequence of DNA that directs the transcription of a gene. A promoter may direct the transcription of a prokaryotic or eukaryotic gene. A promoter may be “inducible”, initiating transcription in response to an inducing agent or, in contrast, a promoter may be “constitutive”, whereby an inducing agent does not regulate the rate of transcription. A promoter may be regulated in a tissue-specific or tissue-preferred manner, such that it is only active in transcribing the operable linked coding region in a specific tissue type or types.

The term “pulse voltage device,” or “pulse voltage injection device” as used herein relates to an apparatus that is capable of causing or causes uptake of nucleic acid molecules into the cells of an organism by emitting a localized pulse of electricity to the cells. The cell membrane then destabilizes, forming passageways or pores. Conventional devices of this type are calibrated to allow one to select or adjust the desired voltage amplitude and the duration of the pulsed voltage. The primary importance of a pulse voltage device is the capability of the device to facilitate delivery of compositions of the invention, particularly new plasmids with optimized expression cassettes and plasmid backbone, into the cells of the organism.

The term “replication element” as used herein comprises nucleic acid sequences that will lead to replication of a plasmid in a specified host. One skilled in the art of molecular biology will recognize that the replication element may include, but is not limited to a selectable marker gene promoter, a ribosomal binding site, a selectable marker gene sequence, and a origin of replication.

The term “secretagogue” as used herein refers to an agent that stimulates secretion. For example, a growth hormone secretagogue is any molecule that stimulates the release of growth hormone from the pituitary when delivered into an animal. Growth hormone releasing hormone is a growth hormone secretagogue.

The terms “subject” or “animal” as used herein refers to any species of the animal kingdom. In preferred embodiments, it refers more specifically to humans and domesticated animals used for: pets (e.g. cats, dogs, etc.); work (e.g. horses, etc.); food (cows, chicken, fish, lambs, pigs, etc); and all others known in the art.

The term “therapeutic element” as used herein comprises nucleic acid sequences that will lead to an in vivo expression of an encoded gene product. One skilled in the art of molecular biology will recognize that the therapeutic element may include, but is not limited to a promoter sequence, a poly(A) sequence, or a 3′ or 5′ UTR.

The term “tissue” as used herein refers to a collection of similar cells and the intercellular substances surrounding them. A skilled artisan recognizes that a tissue is an aggregation of similarly specialized cells for the performance of a particular function. For the scope of the present invention, the term tissue does not refer to a cell line, a suspension of cells, or a culture of cells. In a specific embodiment, the tissue is electroporated in vivo. In another embodiment, the tissue is not a plant tissue. A skilled artisan recognizes that there are four basic tissues in the body: 1) epithelium; 2) connective tissues, including blood, bone, and cartilage; 3) muscle tissue; and 4) nerve tissue. In a specific embodiment, the methods and compositions are directed to transfer new optimized plasmids into a muscle tissue by electroporation.

The term “transfects” as used herein refers to introduction of a nucleic acid into a eukaryotic cell. In some embodiments, the cell is not a plant tissue or a yeast cell.

The term “vector” as used herein refers to any vehicle that delivers a nucleic acid into a cell or organism. Examples include plasmid vectors, viral vectors, liposomes, or cationic lipids.

The term “viral backbone” as used herein refers to a nucleic acid sequence that does may contain a promoter, a gene, and a 3′ poly A signal or an untranslated region, but contain elements including, but not limited at site-specific genomic integration Rep and inverted terminal repeats (“ITRs”) or the binding site for the tRNA primer for reverse transcription, or a nucleic acid sequence component that induces a viral immunogenicity response when inserted in vivo, allows integration, affects specificity and activity of tissue specific promoters, causes transcriptional silencing or poses safety risks to the subject.

The new synthetic constructs of the current invention are injected intramuscularly into a correspondent species. For example, the porcine GHRH (“pGHRH”) construct in any version is utilized in pigs. Although not wanting to be bound by theory, the porcine GHRH will be produced by the pig muscle fibers, and then secreted into the circulatory system. The circulating hormone will enhance the synthesis and secretion of porcine growth hormone in the anterior pituitary. The new synthetic constructs can promote long-term expression because the new plasmid backbone lacks CpG islands and other bacterial components, as bacterial promoters that alert the immune system of the presence of a foreign antigen. By decreasing the immune response against the plasmid fragment and its products can function in the muscle cells for longer durations of time, which lowers cost of treatment by decreasing the number of treatments. Furthermore, the usage of species-specific transgene will ensure long term expression by the lack of neutralizing antibodies against a foreign GHRH.

Plasmid-mediated supplementation. The delivery of specific genes to somatic tissue in a manner that can correct inborn or acquired deficiencies and imbalances has been demonstrated in prior art. Plasmid-mediated transgene supplementation for therapeutic purposes offers a number of advantages over the administration of recombinant proteins. These advantages include the conservation of native protein structure, improved biological activity, avoidance of systemic toxicities, and avoidance of infectious and toxic impurities. In addition, plasmid-mediated transgene supplementation allows for prolonged exposure to the protein in the therapeutic range, because the newly secreted protein is present continuously in the blood circulation.

Although not wanting to be bound by theory, the primary limitation of using a recombinant protein is the limited availability of protein after each administration. Plasmid mediated gene supplementation using injectable DNA plasmid expression vectors overcomes this drawback, because a single injection into the subject's skeletal muscle permits physiologic expression for extensive periods of time (Brown et al., 2004; Tone et al., 2004). Injection of the plasmids can promote the production of enzymes and hormones in animals in a manner that more closely mimics the natural process. Furthermore, among the non-viral techniques for gene transfer in vivo, the direct injection of plasmid DNA into muscle tissue is simple, inexpensive, and safe.

In a plasmid based expression system, a non-viral transgene vector may be composed of a synthetic gene delivery system in addition to the nucleic acid encoding a therapeutic gene product. In this way, the risks associated with the use of most viral vectors can be avoided. Additionally, no integration of plasmid sequences into host chromosomes has been reported in vivo to date, so that this type of gene transfer should neither activate oncogenes nor inactivate tumor suppressor genes (Ledwith et al., 2000b; Ledwith et al., 2000a). As episomal systems residing outside the chromosomes, plasmids have defined pharmacokinetics and elimination profiles, leading to a finite duration of gene expression in target tissues (Manam et al., 2000).

One aspect of the current invention is a new, versatile, and codon optimized plasmid based mammalian expression system that can be produced at high yields, which can be delivered to the target host and will reduce the adverse effects associated with prokaryotic nucleic acid sequences in mammalian hosts. In addition, this new plasmid will constitute the base of a species-specific library of plasmids for expression of hormones or other proteins for agricultural and companion animal applications. The synthetic expression plasmid of this invention has further reduced components compared to our and other previous applications, and has been optimized to increase efficacy, and reduce adverse reactions in vivo. In addition to a mammalian gene of interest, a typical nucleic acid delivery vehicle or synthetic expression plasmid contains many structural elements useful for the in vitro amplification of the plasmid in a bacterial host. The current invention involves a “synthetic plasmid backbone” (“pAV0201”) (SEQ ID NO.: 2) that provides a clean lineage, which is useful for plasmid supplementation therapy in mammals. Furthermore, new plasmid backbones, such as “pAV0224” (SEQ ID NO.: 12), “pAV0225” (SEQ ID NO.: 13), “pAV0237” (SEQ ID NO.: 14), “pAV0242” (SEQ ID NO.: 15), and finally the “mut” family (SEQ ID NO.: 31-35) plasmid backbone family has been optimized for plasmid production, smaller than previous versions, and with optimized origin of replication.

A plasmid based mammalian expression system is minimally composed of a plasmid backbone, a synthetic delivery promoter in addition to the nucleic acid encoding a therapeutic expression product. A plasmid backbone typically contains a bacterial origin of replication, and a bacterial antibiotic selection gene, which are necessary for the specific growth of only the bacteria that are transformed with the proper plasmid. However, there are plasmids that lack both the antibiotic resistance gene and the origin of replication, such plasmids are called mini-circles (Darquet et al., 1997; Darquet et al., 1999; Soubrier et al., 1999). The use of in vitro amplified expression plasmid DNA (i.e. non-viral expression systems) avoids the risks associated with viral vectors. The non-viral expression systems products generally have low toxicity due to the use of “species-specific” components for gene delivery, which minimizes the risks of immunogenicity generally associated with viral vectors. One aspect of the current invention is a new, versatile, and codon optimized plasmid based mammalian expression system, which will constitute the base of a species-specific library of plasmids for expression of hormones or other proteins for agricultural and companion animal applications. For example, optimized synthetic sequences can be produced such that codon frequencies are matched in target and host organisms to ensure proper folding. A bias of GC content can be used to increase mRNA stability or reduce secondary structures. Tandem repeat codons or base runs that may impair the gene can be minimized with codon optimization. Modification of ribosome binding sites and mRNA degradation sites can be utilized. Optimization can also reduce or eliminate problem secondary structures within the transcribed mRNA, as well as optimizing RNAII activity.

Vectors. The term “vector” is used to refer to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted for introduction into a cell wherein, in some embodiments, it can be replicated. A nucleic acid sequence can be native to the animal, or it can be “exogenous,” which means that it is foreign to the cell into which the vector is being introduced or that the sequence is homologous to a sequence in the cell but in a position within the host cell nucleic acid in which the sequence is ordinarily not found. Vectors include plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), linear DNA fragments, and artificial chromosomes (e.g., YACs), although in a preferred embodiment the vector contains substantially no viral sequences. One of skill in the art would be well equipped to construct a vector through standard recombinant techniques.

The term “expression vector” refers to a vector or nucleic acid expression construct containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In a specific embodiment the nucleic acid sequence encodes part or all of GHRH. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. In other cases, these sequences are not translated, for example, in the production of antisense molecules or ribozymes. Expression vectors can contain a variety of “control sequences,” which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence in a particular host organism. In addition to control sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well and are described infra.

In a preferred embodiment, the nucleic acid construction construct or vector of the present invention is a plasmid which comprises a synthetic myogenic (muscle-specific) promoter, a synthetic nucleotide sequence encoding a species specific growth hormone releasing hormone or its analogs, and a 3′ untranslated region. In other alternative embodiments, optimized porcine growth hormone, optimized human growth hormone, optimized mouse growth hormone, optimized rat growth hormone, optimized bovine growth hormone, optimized ovine growth hormone, optimized chicken growth hormone, or skeletal alpha actin 3′ untranslated regions are utilized in the vector.

Plasmid vectors. In certain embodiments, a linear DNA fragment from a plasmid vector is contemplated for use to transfect a eukaryotic cell, particularly a mammalian cell. In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells. In a non-limiting example, E. coli is often transformed using derivatives of pBR322, a plasmid derived from an E. coli species. pBR322 contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. Other plasmids contain genes for kanamycin or neomycin, or have a non-antibiotic selection mechanism. The pBR plasmid, or other microbial plasmid or phage must also contain, or be modified to contain, for example, promoters which can be used by the microbial organism for expression of its own proteins. A skilled artisan recognizes that any plasmid in the art may be modified for use in the methods of the present invention. In a specific embodiment, for example, a GHRH vector used for the therapeutic applications is derived from pBlueScript KS+ and has a kanamycin resistance gene.

In addition, phage vectors containing replicon and control sequences that are compatible with the host microorganism can be used as transforming vectors in connection with these hosts. For example, the phage lambda GEM™-11 may be utilized in making a recombinant phage vector which can be used to transform host cells, such as, for example, E. coli LE392.

Further useful plasmid vectors include pIN vectors (Inouye et al., 1985); and pGEX vectors, for use in generating glutathione S-transferase (“GST”) soluble fusion proteins for later purification and separation or cleavage. Other suitable fusion proteins are those with β-galactosidase, ubiquitin, and the like.

Bacterial host cells, for example, E. coli, comprising the expression vector, are grown in any of a number of suitable media, for example, LB or its derivates. The expression of the recombinant protein in certain vectors may be induced, as would be understood by those of skill in the art, by contacting a host cell with an agent specific for certain promoters, e.g., by adding IPTG to the media or by switching incubation to a higher temperature. After culturing the bacteria for a further period, generally of between 2 and 24 hours, the cells are collected by centrifugation and washed to remove residual media.

Promoters and Enhancers. A “promoter” is a control sequence that is a region of a nucleic acid sequence at which initiation and rate of transcription are controlled. It may contain genetic elements at which regulatory proteins and molecules may bind such as RNA polymerase and other transcription factors. The phrases “operatively positioned,” “operatively linked,” “under control” and “under transcriptional control” mean that a promoter is in a correct functional location and/or orientation in relation to a nucleic acid sequence to control transcriptional initiation and/or expression of that sequence. A promoter may or may not be used in conjunction with an “enhancer,” which refers to a cis-acting regulatory sequence involved in the transcriptional activation of a nucleic acid sequence.

A promoter generally comprises a sequence that functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as, for example, the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation. Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have been shown to contain functional elements downstream of the start site as well. To bring a coding sequence “under the control of” a promoter, one positions the 5′ end of the transcription initiation site of the transcriptional reading frame “downstream” (i.e., 3′ of) the chosen promoter. The “upstream” promoter stimulates transcription of the DNA and promotes expression of the encoded RNA.

The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. For instance, in the timidine kinase (TK) promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription. A promoter may or may not be used in conjunction with an “enhancer,” which refers to a cis-acting regulatory sequence involved in the transcriptional activation of a nucleic acid sequence.

The distance between the eukaryotic promoter from the expression cassette and prokaryotic elements within plasmid backbone is also critical. In a specific embodiment in this application, we reduced the distance between the eukaryotic promoter SPc5-12 and the kanamycin resistance gene and control elements without impairment of plasmid production.

A promoter may be one naturally associated with a nucleic acid sequence, as may be obtained by isolating the 5′ non-coding sequences located upstream of the coding segment and/or exon. Such a promoter can be referred to as “endogenous.” Similarly, an enhancer may be one naturally associated with a nucleic acid sequence, located either downstream or upstream of that sequence. Alternatively, certain advantages will be gained by positioning the coding nucleic acid segment under the control of a recombinant, synthetic or heterologous promoter, which refers to a promoter that is not normally associated with a nucleic acid sequence in its natural environment. A recombinant, synthetic or heterologous enhancer refers also to an enhancer not normally associated with a nucleic acid sequence in its natural environment. Such promoters or enhancers may include promoters or enhancers of other genes, and promoters or enhancers isolated from any other virus, or prokaryotic or eukaryotic cell, and promoters or enhancers not “naturally occurring,” i.e., containing different elements of different transcriptional regulatory regions, and/or mutations that alter expression. For example, promoters that are most commonly used in recombinant DNA construction include the β-lactamase (penicillinase), lactose and tryptophan (trp) promoter systems. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, sequences may be produced using recombinant cloning and/or nucleic acid amplification technology, including PCR™, in connection with the compositions disclosed herein (see U.S. Pat. Nos. 4,683,202 and 5,928,906, each incorporated herein by reference). Furthermore, it is contemplated the control sequences that direct transcription and/or expression of sequences within non-nuclear organelles such as mitochondria, chloroplasts, and the like, can be employed as well.

Naturally, it will be important to employ a promoter and/or enhancer that effectively directs the expression of the DNA segment in the organelle, cell type, tissue, organ, or organism chosen for expression. Those of skill in the art of molecular biology generally know the use of promoters, enhancers, and cell type combinations for protein expression. The promoters employed may be constitutive, tissue-specific, inducible, and/or useful under the appropriate conditions to direct high level expression of the introduced DNA segment, such as is advantageous in the large-scale production of recombinant proteins and/or peptides. The promoter may be heterologous or endogenous. Additionally, many Eukaryotic Promoter promoter/enhancer combination that would available to one of ordinary skill in the art could also be used to drive expression.

Use of a T3, T7 or SP6 cytoplasmic expression system is another possible embodiment. Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct. While most classic plasmids contain these elements, their usage is not always justified in highly specialized or optimized plasmids.

Tables 1 and 2 list non-limiting examples of elements/promoters that may be employed, in the context of the present invention, to regulate the expression of the eukaryotic RNA. Table 2 provides non-limiting examples of inducible elements, which are regions of a nucleic acid sequence that can be activated in response to a specific stimulus. TABLE 1 Promoter and/or Enhancer Promoter/Enhancer Relevant References β-Actin (Kawamoto et al., 1988; Kawamoto et al., 1989) Muscle Creatine (Horlick and Benfield, 1989; Jaynes et al., 1988) Kinase (MCK) Metallothionein (Inouye et al., 1994; Narum et al., 2001; (MTII) Skroch et al., 1993) Albumin (Pinkert et al., 1987; Tronche et al., 1989) β-Globin (Tronche et al., 1990; Trudel and Costantini, 1987) Insulin (German et al., 1995; Ohlsson et al., 1991) Rat Growth Hormone (Larsen et al., 1986) Troponin I (TN I) (Lin et al., 1991; Yutzey and Konieczny, 1992) Platelet-Derived (Pech et al., 1989) Growth Factor (PDGF) Duchenne Muscular (Klamut et al., 1990; Klamut et al., 1996) Dystrophy Cytomegalovirus (Boshart et al., 1985; Dorsch-Hasler et al., 1985) (CMV) Synthetic muscle (Draghia-Akli et al., 1999; Draghia-Akli et al., specific promoters 2002c; Li et al., 1999) (c5-12, c1-28)

TABLE 2 Element/Inducer Element Inducer MT II Phorbol Ester (TFA) Heavy metals MMTV (mouse mammary tumor Glucocorticoids virus) β-Interferon Poly(rI)x/Poly(rc) Adenovirus 5 E2 ElA Collagenase Phorbol Ester (TPA) Stromelysin Phorbol Ester (TPA) SV40 Phorbol Ester (TPA) Murine MX Gene Interferon, Newcastle Disease Virus GRP78 Gene A23187 α-2-Macroglobulin IL-6 Vimentin Serum MHC Class I Gene H-2 κb Interferon HSP70 ElA, SV40 Large T Antigen Proliferin Phorbol Ester-TPA Tumor Necrosis Factor α PMA Thyroid Stimulating Hormone α Thyroid Hormone Gene

The identity of tissue-specific promoters or elements, as well as assays to characterize their activity, is well known to those of skill in the art. Non-limiting examples of such regions include the human LIMK2 gene (Nomoto et al., 1999), the somatostatin receptor 2 gene (Kraus et al., 1998), murine epididymal retinoic acid-binding gene (Lareyre et al., 1999), human CD4 (Zhao-Emonet et al., 1998), mouse alpha2 (XI) collagen (Liu et al., 2000; Tsumaki et al., 1998), D1A dopamine receptor gene (Lee et al., 1997), insulin-like growth factor II (Dai et al., 2001; Wu et al., 1997), and human platelet endothelial cell adhesion molecule-1 (Almendro et al., 1996).

In a preferred embodiment, a synthetic muscle promoter is utilized, such as SPc5-12 (Li et al., 1999), which contains a proximal serum response element (“SRE”) from skeletal α-actin, multiple MEF-2 sites, MEF-1 sites, and TEF-1 binding sites, and greatly exceeds the transcriptional potencies of natural myogenic promoters. The uniqueness of such a synthetic promoter is a significant improvement over, for instance, issued patents concerning a myogenic promoter and its use (e.g. U.S. Pat. No. 5,374,544) or systems for myogenic expression of a nucleic acid sequence (e.g. U.S. Pat. No. 5,298,422). In a preferred embodiment, the promoter utilized in the invention does not get shut off or reduced in activity significantly by endogenous cellular machinery or factors. Other elements, including trans-acting factor binding sites and enhancers may be used in accordance with this embodiment of the invention. In an alternative embodiment, a natural myogenic promoter is utilized, and a skilled artisan is aware how to obtain such promoter sequences from databases including the National Center for Biotechnology Information (“NCBI”) GenBank database or the NCBI PubMed site. A skilled artisan is aware that these databases may be utilized to obtain sequences or relevant literature related to the present invention.

Initiation Signals and Internal Ribosome Binding Sites. A specific initiation signal also may be required for efficient translation of coding sequences. These signals include the ATG initiation codon or adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. It is well known that the initiation codon must be “in-frame” with the reading frame of the desired coding sequence to ensure translation of the entire insert. The exogenous translational control signals and initiation codons can be either natural or synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements.

In certain embodiments of the invention, the use of internal ribosome entry sites (IRES) elements are used to create multigene, or polycistronic, messages. IRES elements are able to bypass the ribosome scanning model of 5′ methylated Cap dependent translation and begin translation at internal sites. IRES elements from two members of the picornavirus family (polio and encephalomyocarditis) (Pelletier and Sonenberg, 1988) have been described, as well IRES from mammalian messages (Lyons and Robertson, 2003; Macejak and Sarnow, 1991; Martineau et al., 2004). IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message (see U.S. Pat. Nos. 5,925,565 and 5,935,819, each herein incorporated by reference)

Multiple Cloning Sites. Vectors can include a MCS, which is a nucleic acid region that contains multiple restriction enzyme sites, any of which can be used in conjunction with standard recombinant technology to digest the vector (see, for example, (Carbonelli et al., 1999; Cocea, 1997; Levenson et al., 1998) incorporated herein by reference.) “Restriction enzyme digestion” refers to catalytic cleavage of a nucleic acid molecule with an enzyme that functions only at specific locations in a nucleic acid molecule. Many of these restriction enzymes are commercially available. Use of such enzymes is widely understood by those of skill in the art. Frequently, a vector is linearized or fragmented using a restriction enzyme that cuts within the MCS to enable exogenous sequences to be ligated to the vector. “Ligation” refers to the process of forming phosphodiester bonds between two nucleic acid fragments, which may or may not be contiguous with each other. Techniques involving restriction enzymes and ligation reactions are well known to those of skill in the art of recombinant technology, used and described herein in “Examples”. While the regions are necessary for creating a library of multipurpose plasmids, their excessive presence, through numerous rounds of cloning parts of preexistent plasmids or fragments can potentially generate cryptic transcription initiation sites, stop codons, or other sequences that interfere with plasmid expression or production. Thus, in our new optimized plasmids cloning sites are kept to a necessary minimum.

Restriction Enzymes. In some embodiments of the present invention, a linear DNA fragment is generated by restriction enzyme digestion of a parent DNA molecule. The fragments are then ligated together, or with other newly produced linear DNA fragments, generating new plasmids or DNA fragments. Examples of restriction enzymes are provided below. Name Recognition Sequence AatII GACGTC Acc65 I GGTACC Acc I GTMKAC Aci I CCGC Acl I AACGTT Afe I AGCGCT Afl II CTTAAG Afl III ACRYGT Age I ACCGGT Ahd I GACNNNNNGTC Alu I AGCT Alw I GGATC AlwN I CAGNNNCTG Apa I GGGCCC AnaL I GTGCAC Ano I RAATTY Asc I GGCGCGCC Ase I ATTAAT Ava I CYCGRG Ava II GGWCC Avr II CCTAGG Bae I NACNNNNGTAPyCN BamH I GGATCC Ban I GGYRCC Ban II GRGCYC Bbs I GAAGAC Bbv I GCAGC BbvC I CCTCAGC Bcg I CGANNNNNNTGC BciV I GTATCC Bcl I TGATCA Bfa I CTAG Bgl I GCCNNNNNGGC Bgl II AGATCT Blp I GCTNAGC Bmr I ACTGGG Bpm I CTGGAG BsaA I YACGTR BsaB I GATNNNNATC BsaH I GRCGYC Bsa I GGTCTC BsaJ I CCNNGG BsaW I WCCGGW BseR I GAGGAG Bsg I GTGCAG BsiE I CGRYCG BsiHKA I GWGCWC BsiW I CGTACG Bsl I CCNNNNNNNGG BsmA I GTCTC BsmB I CGTCTC BsmF I GGGAC Bsm I GAATGC BsoB I CYCGRG Bsp 1286 I GDGCHC BspD I ATCGAT BspE I TCCGGA BspH I TCATGA BsnM I ACCTGC BsrB I CCGCTC BsrD I GCAATG BsrF I RCCGGY BsrG I TGTACA Bsr I ACTGG BssH II GCGCGC BssK I CCNGG Bst4C I ACNGT BssS I CACGAG BstAP I GCANNNNNTGC BstB I TTCGAA BstE II GGTNACC BstF5 I GGATGNN BstN I CCWGG BstU I CGCG BstX I CCANNNNNNTGG BstY I RGATCY BstZ17 I GTATAC Bsu36 I CCTNAGG Btg I CCPuPyGG Btr I CACGTG Cac8 I GCNNGC Cla I ATCGAT Dde I CTNAG Dpn I GATC Dpn II GATC Dra I TTTAAA Dra III CACNNNGTG Drd I GACNNNNNNGTC Eae I YGGCCR Eag I CGGCCG Ear I CTCTTC Eci I GGCGGA EcoN I CCTNNNNNAGG EcoO109 I RGGNCCY EcoR I GAATTC EcoR V GATATC Fau I CCCGCNNNN Fnu4H I GCNGC Fok I GGATG Fse I GGCCGGCC Fsp I TGCGCA Hae II RGCGCY Hae III GGCC Hga I GACGC Hha I GCGC Hinc II GTYRAC Hind III AAGCTT Hinf I GANTC HinP1 I GCGC Hpa I GTTAAC Hpa II CCGG Hph I GGTGA Kas I GGCGCC Kpn I GGTACC Mbo I GATC Mbo II GAAGA Mfe I CAATTG Mlu I ACGCGT Mly I GAGTCNNNNN Mnl I CCTC Msc I TGGCCA Mse I TTAA Msl I CAYNNNNRTG MsnA1 I CMGCKG Msp I CCGG Mwo I GCNNNNNNNGC Nae I GCCGGC Nar I GGCGCC Nci I CCSGG Nco I CCATGG Nde I CATATG N2oM1 V GCCGGC Nhe I GCTAGC Nla III CATG Nla IV GGNNCC Not I GCGGCCGC Nru I TCGCGA Nsi I ATGCAT Nsp I RCATGY Pac I TTAATTAA PaeR7 I CTCGAG Pci I ACATGT PflF I GACNNNGTC PflM I CCANNNNNTGG PleI GAGTC Pme I GTTTAAAC Pml I CACGTG PpuM I RGGWCCY PshA I GACNNNNGTC Psi I TTATAA PsaG I CCWGG PspOM I GGGCCC Pst I CTGCAG Pvu I CGATCG Pvu II CAGCTG Rsa I GTAC Rsr ll CGGWCCG Sac I GAGCTC Sac II CCGCGG Sal I GTCGAC Sap I GCTCTTC Sau3A I GATC Sau96 I GGNCC Sbf I CCTGCAGG Sca I AGTACT ScrF I CCNGG SexA I ACCWGGT SfaN I GCATC Sfc I CTRYAG Sfi I GGCCNNNNNGGCC Sfo I GGCGCC SgrA I CRCCGGYG Sma I CCCGGG Sml I CTYRAG SnaB I TACGTA Spe I ACTAGT Sph I GCATGC Ssp I AATATT Stu I AGGCCT Sty I CCWWGG Swa I ATTTAAAT Tag I TCGA Tfi I GAWTC Tli I CTCGAG Tse I GCWGC Tsp45 I GTSAC Tsp509 I AATT TspR I CAGTG Tth111 I GACNNNGTC Xba I TCTAGA Xcm I CCANNNNNNNNNTGG Xho I CTCGAG Xma I CCCGGG Xmn I GAANNNNTTC

The term “restriction enzyme digestion” of DNA as used herein refers to catalytic cleavage of the DNA with an enzyme that acts only at certain locations in the DNA. Such enzymes are called restriction endonucleases and the sites for which each is specific is called a restriction site. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors, and other requirements as established by the enzyme suppliers are used. Restriction enzymes commonly are designated by abbreviations composed of a capital letter followed by other letters representing the microorganism from which each restriction enzyme originally was obtained and then a number designating the particular enzyme. In general, about 1 μg of plasmid or DNA fragment is used with about 1-2 units of enzyme in about 20 μL of buffer solution. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Restriction enzymes are used to ensure plasmid integrity and correctness. The specific restriction enzymes used in each reaction is given in the “Examples”.

Splicing Sites. Most transcribed eukaryotic RNA molecules will undergo RNA splicing to remove introns from the primary transcripts. Vectors containing genomic eukaryotic sequences may require donor and/or acceptor splicing sites to ensure proper processing of the transcript for protein expression (see for example (Chandler et al., 1997).

Termination Signals. The vectors or constructs of the present invention will generally comprise at least one termination signal. A “termination signal” or “terminator” is comprised of the DNA sequences involved in specific termination of an RNA transcript by an RNA polymerase. Thus, in certain embodiments a termination signal that ends the production of an RNA transcript is contemplated. A terminator may be necessary in vivo to achieve desirable message levels.

In eukaryotic systems, the terminator region may also comprise specific DNA sequences that permit site-specific cleavage of the new transcript so as to expose a polyadenylation site. This signals a specialized endogenous polymerase to add a stretch of about 200 A residues or “poly(A)” to the 3′end of the transcript. RNA molecules modified with this poly(A) tail appear to more stable and are translated more efficiently. Thus, in other embodiments involving eukaryotes, it is preferred that that terminator comprises a signal for the cleavage of the RNA, and it is more preferred that the terminator signal promotes polyadenylation of the message. The terminator and/or polyadenylation site elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.

Terminators contemplated for use in the invention include any known terminator of transcription described herein or known to one of ordinary skill in the art, including but not limited to, for example, the termination sequences of genes, such as for example the bovine growth hormone terminator or viral termination sequences, such as for example the SV40 terminator. In certain embodiments, the termination signal may be a lack of transcribable or translatable sequence, such as due to a sequence truncation.

Polyadenylation Signals. In expression, one will typically include a polyadenylation signal to effect proper polyadenylation of the transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and/or any such sequence may be employed. Preferred embodiments include the bovine or human growth hormone polyadenylation signal, convenient and/or known to function well in various target cells. Also contemplated as an element of the expression cassette is a transcriptional termination site. These elements can serve to enhance message levels and/or to minimize read through from the cassette into other sequences.

Origins of Replication. In order to propagate a vector in a host cell, it may contain one or more origins of replication sites (often termed “ori”), which is a specific nucleic acid sequence at which replication is initiated. Alternatively an autonomously replicating sequence (ARS) can be employed if the host cell is yeast.

Selectable and Screenable Markers. In certain embodiments of the invention, the cells that contain the nucleic acid construct of the present invention may be identified in vitro or in vivo by including a marker in the expression vector. Such markers would confer an identifiable change to the cell permitting easy identification of cells containing the expression vector. Generally, a selectable marker is one that confers a property that allows for selection. A positive selectable marker is one in which the presence of the marker allows for its selection, while a negative selectable marker is one in which its presence prevents its selection. An example of a positive selectable marker is a drug resistance marker, such as the antibiotic resistance gene on the plasmid constructs (such as kanamycin, ampicylin, gentamycin, tetracycline, or chloramphenicol).

Usually the inclusion of a drug selection marker aids in the cloning and identification of transformants, for example, genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selectable markers. In addition to markers conferring a phenotype that allows for the discrimination of transformants based on the implementation of conditions, other types of markers including screenable markers such as GFP, whose basis is colorimetric analysis, are also contemplated. Alternatively, screenable enzymes may be utilized. One of skill in the art would also know how to employ immunologic markers, possibly in conjunction with FACS analysis. The marker used is not believed to be important, so long as it is capable of being expressed simultaneously with the nucleic acid encoding a gene product. Further examples of selectable and screenable markers are well known to one of skill in the art.

Mutagenesis. Where employed, mutagenesis was accomplished by a variety of standard, mutagenic procedures. Mutation is the process whereby changes occur in the quantity or structure of an organism. Mutation can involve modification of the nucleotide sequence of a single gene, blocks of genes or whole chromosome. Changes in single genes may be the consequence of point mutations which involve the removal, addition or substitution of a single nucleotide base within a DNA sequence, or they may be the consequence of changes involving the insertion or deletion of large numbers of nucleotides.

Mutations can arise spontaneously as a result of events such as errors in the fidelity of DNA replication or the movement of transposable genetic elements (transposons) within the genome. They also are induced following exposure to chemical or physical mutagens. Such mutation-inducing agents include ionizing radiations, ultraviolet light and a diverse array of chemical such as alkylating agents and polycyclic aromatic hydrocarbons all of which are capable of interacting either directly or indirectly (generally following some metabolic biotransformations) with nucleic acids. The DNA lesions induced by such environmental agents may lead to modifications of base sequence when the affected DNA is replicated or repaired and thus to a mutation. Mutation also can be site-directed through the use of particular targeting methods.

Site-Directed Mutagenesis. Structure-guided site-specific mutagenesis represents a powerful tool for the dissection and engineering of protein-ligand interactions (Zheng and Kyle, 1996). The technique provides for the preparation and testing of sequence variants by introducing one or more nucleotide sequence changes into a selected DNA (Ryu and Nam, 2000).

Site-specific mutagenesis uses specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent, unmodified nucleotides. In this way, a primer sequence is provided with sufficient size and complexity to form a stable duplex on both sides of the deletion junction being traversed. A primer of about 17 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered.

The technique typically employs a bacteriophage vector that exists in both a single-stranded and double-stranded form. Vectors useful in site-directed mutagenesis include vectors such as the M13 phage. These phage vectors are commercially available and their use is generally well known to those skilled in the art. Double-stranded plasmids are also routinely employed in site-directed mutagenesis, which eliminates the step of transferring the gene of interest from a phage to a plasmid.

In general, one first obtains a single-stranded vector, or melts two strands of a double-stranded vector, which includes within its sequence a DNA sequence encoding the desired protein or genetic element. An oligonucleotide primer bearing the desired mutated sequence, synthetically prepared, is then annealed with the single-stranded DNA preparation, taking into account the degree of mismatch when selecting hybridization conditions. The hybridized product is subjected to DNA polymerizing enzymes such as E. Coli polymerase I (Klenow fragment) in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed, wherein one strand encodes the original non-mutated sequence, and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate host cells, such as E. coli cells, and clones are selected that include recombinant vectors bearing the mutated sequence arrangement. The shortcoming of this approach is that the logistics of multi-residue saturation mutagenesis are daunting. Hundreds, and possibly even thousands, of site specific mutants must be studied. However, improved techniques make production and rapid screening of mutants much more straightforward. See also, U.S. Pat. Nos. 5,798,208 and 5,830,650, for a description of “walk-through” mutagenesis. Other methods of site-directed mutagenesis are disclosed in U.S. Pat. Nos. 5,220,007; 5,284,760; 5,354,670; 5,366,878; 5,389,514; 5,635,377; and 5,789,166.

Alternatively, newer site-directed mutagenesis techniques can be used, such as “gene-trap mutagenesis”. Gene-trap mutagenesis is a technique that randomly generates loss-of-function mutations and reports the expression of many mouse genes (Stanford et al., 2001). Alternatively, PCR can be used for side-directed mutagenesis (Jenkins et al., 1999). The PCR primers will contain the desired mutation, and the resulting fragment can be cloned in the plasmid using standard molecular biology techniques. This method was preferred and used in our “Examples”.

Electroporation. A nucleic acid can be introduced into an organelle, a cell, a tissue or an organism via electroporation. Electroporation involves the exposure of a population of cells and DNA to an electric discharge.

Transfection of eukaryotic cells using electroporation has been quite successful. Mouse pre-B lymphocytes have been transfected with human kappa-immunoglobulin genes (Potter et al., 1984), and rat hepatocytes have been transfected with the chloramphenicol acetyltransferase gene (Tur-Kaspa et al., 1986) in this manner.

The underlying phenomenon of electroporation is believed to be the same in all cases, but the exact mechanism responsible for the observed effects has not been elucidated. Although not wanting to be bound by theory, the overt manifestation of the electroporative effect is that cell membranes become transiently permeable to large molecules after the cells have been exposed to electric pulses. There are conduits through cell walls, which under normal circumstances maintain a resting transmembrane potential of circa 90 mV by allowing bi-directional ionic migration.

Although not wanting to be bound by theory, electroporation makes use of the same structures, by forcing a high ionic flux through these structures and opening or enlarging the conduits. In prior art, metallic electrodes are placed in contact with tissues and predetermined voltages, proportional to the distance between the electrodes are imposed on them. The protocols used for electroporation are defined in terms of the resulting field intensities, according to the formula E=V/d, where (“E”) is the field, (“V”) is the imposed voltage and (“d”) is the distance between the electrodes.

The electric field intensity E has been a very important value in prior art when formulating electroporation protocols for the delivery of a drug or macromolecule into the cell of the subject. Accordingly, it is possible to calculate any electric field intensity for a variety of protocols by applying a pulse of predetermined voltage that is proportional to the distance between electrodes. However, a caveat is that an electric field can be generated in a tissue with insulated electrodes (i.e. flow of ions is not necessary to create an electric field). Although not wanting to be bound by theory, it is the current that is necessary for successful electroporation not electric field per se.

During electroporation, the heat produced is the product of the inter-electrode impedance, the square of the current, and the pulse duration. The protocols described in the art for electroporation are defined in terms of the resulting field intensities E, which are dependent on short voltage pulses of unknown current. Accordingly, the resistance or heat generated in a tissue cannot be determined, which leads to varied success with different pulsed voltage electroporation protocols with predetermined voltages. The ability to limit heating of cells across electrodes can increase the effectiveness of any given electroporation voltage pulsing protocol. For example, prior art teaches the utilization of an array of six needle electrodes utilizing a predetermined voltage pulse across opposing electrode pairs. This situation sets up a centralized pattern during an electroporation event in an area where congruent and intersecting overlap points develop. Excessive heating of cells and tissue along electroporation path will kill the cells, and limit the effectiveness of the protocol. However, symmetrically arranged needle electrodes without opposing pairs can produce a decentralized pattern during an electroporation event in an area where no congruent electroporation overlap points can develop.

Controlling the current flow between electrodes allows one to determine the relative heating of cells. Thus, it is the current that determines the subsequent effectiveness of any given pulsing protocol and not the voltage across the electrodes. Predetermined voltages do not produce predetermined currents, and prior art does not provide a means to determine the exact dosage of current, which limits the usefulness of the technique. Thus, controlling an maintaining the current in the tissue between two electrodes under a threshold will allow one to vary the pulse conditions, reduce cell heating, create less cell death, and incorporate macromolecules into cells more efficiently when compared to predetermined voltage pulses.

Overcoming the above problem by providing a means to effectively control the dosage of electricity delivered to the cells in the inter-electrode space by precisely controlling the ionic flux that impinges on the conduits in the cell membranes. The precise dosage of electricity to tissues can be calculated as the product of the current level, the pulse length and the number of pulses delivered. Thus, a specific embodiment of the present invention can deliver the electroporative current to a volume of tissue along a plurality of paths without, causing excessive concentration of cumulative current in any one location, thereby avoiding cell death owing to overheating of the tissue.

Although not wanting to be bound by theory, the nature of the voltage pulse to be generated is determine by the nature of tissue, the size of the selected tissue and distance between electrodes. It is desirable that the voltage pulse be as homogenous as possible and of the correct amplitude. Excessive field strength results in the lysing of cells, whereas low field strength results in reduced efficacy of electroporation. Some electroporation devices utilize the distance between electrodes to calculate the electric field strength and predetermined voltage pulses for electroporation. This reliance on knowing the distance between electrodes is a limitation to the design of electrodes. Because the programmable current pulse controller will determine the impedance in a volume of tissue between two electrodes, the distance between electrodes is not a critical factor for determining the appropriate electrical current pulse. Therefore, an alternative embodiment of a needle electrode array design would be one that is non-symmetrical. In addition, one skilled in the art can imagine any number of suitable symmetrical and non-symmetrical needle electrode arrays that do not deviate from the spirit and scope of the invention. The depth of each individual electrode within an array and in the desired tissue could be varied with comparable results. In addition, multiple injection sites for the macromolecules could be added to the needle electrode array.

One example of an electroporation device that may be used to effectively facilitate the introduction of a macromolecule, including optimized plasmids, into cells of a selected tissue of a subject was described in U.S. patent application Ser. No. 10/657,725 filed on Sep. 8, 2003, titled “Constant Current Electroporation Device And Methods Of Use,” with Smith et al., listed as inventors, the entirety of which is hereby incorporated by reference. The electroporation device comprises an electro-kinetic device (“EKD”) whose operation is specified by software or firmware. The EKD produces a series of programmable constant-current pulse patterns between electrodes in an array based on user control and input of the pulse parameters and allows the storage and acquisition of current waveform data. The electroporation device also comprises a replaceable electrode disk having an array of needle electrodes, a central injection channel for an injection needle, and a removable guide disk.

Without being bound to the theory, the combination of a well-designed plasmid vector with an efficacious delivery method can ensure long-lasting plasmid expression after in vivo treatment with proteins expressed at therapeutic levels.

The invention may be better understood with reference to the following examples which are representative of some of the embodiments of the invention, and are not intended to limit the invention.

EXAMPLE 1 Optimized Plasmid Backbone “pAV0201”

One aspect of the current invention is the optimized plasmid backbone. The new synthetic plasmids presented below contain eukaryotic sequences that are synthetically optimized for species-specific mammalian transcription. Each of the following examples described a step of optimization, each resulting in a new and improved family of plasmids.

An existing pSP-HV-GHRH plasmid (“pAV0125”) (SEQ ID NO.: 1), as shown in FIG. 1 was synthetically optimized to form a new plasmid (“pAV0201”)(SEQ ID NO.: 2), as shown in FIG. 2. The plasmid pAV0125 was described in U.S. patent application Ser. No. 09/624,268 filed on Jul. 24, 2000 and entitled “Super Active Porcine Growth Hormone Releasing Hormone Analog” with Schwartz, et al., listed as inventors, (“the Schwartz '268 application”). This 3,534 bp plasmid pAV0125 (SEQ ID NO.: 1) contains a plasmid backbone with various component from different commercially available plasmids, for example, a synthetic promoter SPc5-12 (SEQ ID NO.: 3), a modified porcine GHRH sequence (SEQ ID NO.: 4), and a 3′end of human growth hormone (SEQ ID NO.: 5).

The new optimized synthetic expression vector “pAV0201” described in U.S. patent application Ser. No. 10/619,939 filed on Jul. 15, 2003 and entitled “Codon-optimized synthetic plasmids” with Draghia-Akli et al. listed as inventors (the '939 application), consists of 2,713 bp and is shown in FIG. 2. The therapeutic encoded gene for the optimized plasmid in FIG. 2 may also include optimized nucleic acid sequences that encode the following modified GHRH molecules:

Encoded GHRH Amino Acid Sequence Wt-pig-GHRH YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGERNQEQGA-OH (SEQID NO.: 17) HV-GHRH HVDAIFTNSYRKVLAQLSARKLLQDILNRQQGERNQEQGA-OH (SEQID NO.: 18) TI-GHRH YIDAIFTNSYRKVLAQLSARKLLQDILNRQQGERNQEQGA-OH (SEQID NO.: 19) TV-GHRH YVDAIFTNSYRKVLAQLSARKLLQDILNRQQGERNQEQGA-OH (SEQID NO.: 20) 15/27/28-GHRH YADAIFTNSYRKVLAQLSARKLLQDILNRQQGERNQEQGA-OH (SEQID NO.: 21) Bovine-GHRH YADAIFTNSYRKVLGQLSARKLLQDIMNRQQGERNQEQGA-OH (SEQID NO.: 22) Dog-GHRH YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGERNREQGA-OH (SEQID NO.: 23) Cat-GHRH YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGERNQEQGA-OH (SEQID NO.: 24) Ovine-GHRH YADAIFTNSYRKILGQLSARKLLQDIMNRQQGERNQEQGA-OH (SEQID NO.: 25) Chicken-GHRH HADGIFSKAYRKLLGQLSARNYLHSLMAKRVGSGLGDEAEPLS-OH (SEQID NO.: 26) Horse-GHRH (partial) -ADAIFTNNYRKVLGQLSARKILQDIMSR-----------OH (SEQID NO.: 27) Human-GHRH(1-40)OH YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGA-OH (SEQID NO.: 28) Human-GHRH(1-44)NH2 YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH₂ (SEQID NO.: 29)

In general, the encoded GHRH or functional biological equivalent thereof is of formula: (SEQID NO.: 30) -X ₁-X ₂-DAIFTNSYRKVL-X ₃-QLSARKLLQDI-X ₄-X ₅-RQQGE-X ₆- N-X ₇-E-X ₈-GA-OH wherein: X₁ is a D- or L-isomer of an amino acid selected from the group consisting of tyrosine (“Y”), or histidine (“H”); X₂ is a D- or L-isomer of an amino acid selected from the group consisting of alanine (“A”), valine (“V”), or isoleucine (“I”); X₃ is a D- or L-isomer of an amino acid selected from the group consisting of alanine (“A”) or glycine (“G”); X₄ is a D- or L-isomer of an amino acid selected from the group consisting of methionine (“M”), or leucine (“L”); X₅ is a D- or L-isomer of an amino acid selected from the group consisting of serine (“S”) or asparagines (“N”); X₆ is a D- or L-isomer of an amino acid selected from the group consisting of arginine (“R”), or serine (“S”); X₇ is a D- or L-isomer of an amino acid selected from the group consisting of arginine (“R”), or glutamine (“Q”); and X₈ is a D- or L-isomer of an amino acid selected from the group consisting of arginine (“R”), or glutamine (“Q”).

An example of this new optimized synthetic expression vector was denoted as pAV0201 (SEQ ID NO.: 2). In order to construct pAV0201 (SEQ ID NO.: 2), some unwanted sequences from the pAV0125 (SEQ ID NO.: 1) were initially removed. A software program called Vector NTI (version 7.0) was used to generate and match sequences that could be compared and were known to be extraneous (e.g. LacZ promoter). There are many programs such as Vector NTI (version 7.0) that are known in the art and could have been used with similar results to compare and identify specific nucleic acid sequences. Once the extraneous DNA sequences were identified in the pAV0125 plasmid, they were removed by from the plasmid creating a truncated-pAV0125 plasmid. The Gene Forge® optimized synthetic sequences were used to produced codon frequencies that were matched in target and host organisms to ensure proper folding. Gene Forge® was also used to identify and correct a number of deleterious structural elements in the relevant nucleic acid sequences. For example, a bias of GC content can be used to increase mRNA stability or reduce secondary structures; tandem repeat codons or base runs that may impair the gene can be minimized with codon optimization; modification of ribosome binding sites and mRNA degradation sites can be utilized; codon optimization can also reduce or eliminate problem secondary structures within the transcribed mRNA. Although Gene Forge® is a proprietary product of Aptagen that speeds codon optimization analysis, publicly available databases are available that allow a person with average skill in the art to replicate codon optimization protocol.

The pAV0125 plasmid contained a human growth hormone polyadenylation region (SEQ ID NO.: 5) that was approximately 618 bp. The original 618 bp region contained multiple polyadenylation sites and was reduced to only one. As a result over 400 bp were removed to an optimized length of 190 bp (SEQ ID NO.: 10). The origin of replication (SEQ ID NO.: 11) was not altered.

A summary of the changes made to the pAV0125 plasmid backbone changes are as follows:

1. Although not wanting to be bound by theory, CpG islands are known to enhance immune responses, and are used to bust immune responses in vaccines (Manders and Thomas, 2000; McCluskie et al., 2000; Scheule, 2000). The Gene Forge® system identified and removed as many CpG island as possible without changing the translated amino acid sequence. A Nco I site was removed from the kanamycin sequence without altering the amino acid sequence. Currently the NcoI became a unique site, which makes the plasmid backbone more versatile.

2. The lacZ promoter region that was located downstream of the hGH polyA site was determined to be unnecessary, and it was subsequently removed.

3. A portion of the hGH poly(A) region was removed to produce a more compact plasmid that is able to accommodate longer DNA fragments or transgenes.

4. A 118 bp portion of the lacZ coding sequence that was located between the kanamycin resistance gene and the C5-12 synthetic promoter was determined to be unnecessary, and it was subsequently removed.

As a result of the above modifications to the plasmid backbone, a new synthetic plasmid as shown in FIG. 2 was constructed. The pAV0201 optimized plasmid comprises a 2,713 bp circular plasmid. The pAV0201 plasmid contains at least one eukaryotic coding region, and at least one prokaryotic coding sequence, wherein it has been contemplated that the eukaryotic coding region contains a modified growth hormone releasing hormone (“GHRH”). The pAV0201 plasmid also contains a poly(A) signal, wherein the human growth hormone poly(A) has been utilized. The pAV0201 plasmid also contains a eukaryotic promoter, and it has been contemplated that the c5-12 synthetic eukaryotic promoter will be used, although other may be equally useful. The pAV0201 also contains a prokaryotic promoter. The prokaryotic promoter is PNEO, and a 19-47 bp sequence of transposon fragment (“Tn5”) with GenBank accession number V00618. Additionally one NEO ribosome binding site (“RBS”) is present in the pAV0201 plasmid. A complementary origin of replication sequence (“pUC ori”) from the pUC18 plasmid (e.g. 685-1466 bp of pUC18). A 5′ untranslated region (“5′UTR”) was inserted into the pAV0201 plasmid. The 5′UTR is from human growth hormone hGH 5′ UTR (i.e. 504-557 bp) GenBank accession number M13438.

EXAMPLE 2 Optimized Plasmid Backbones “pAV0224” and “pAV0237”

The plasmid “pAV0201” was found to have a mutation at position 1581, which changed one nucleotide, “A” present in the wild-type origin of replication with a “G”. The mutation was considered to potentially diminish the plasmid yield compared to the theoretical calculated plasmid yield. Thus, this mutation was corrected by mutagenesis and the newly created plasmid was called “pAV0224” (SEQ ID NO.: 12). The plasmid contained the plasmid backbone, and the expression cassette with the synthetic promoter SPc5-12, the cDNA encoding for the HV-GHRH analog and the 3′UTR and poly(A) signal of GH.

Site specific mutagenesis was performed by overlap extension PCR. Two rounds of PCR were performed to yield the final product. The upper and lower primers contained the base pair changes (A to G sense). Upper primer: 5′GGTAGCTCTTGATCCGGCAAACAAACCACCGCTGG3′ Lower primer: 5′CCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACC3′ NheI primer: 5′CGAGTTCTTCTGAGCGCTAGCTGAG3′ AlwNI primer: 5′CACTGGCAGCAGCCACTGGTAACAG3′

Initial PCR reactions were performed with the “upper” and NheI 3′primers and the “lower” and AlwNI 5′primers. The PCR reaction mix was as following: pAV0201 template—21 ng, 50 ng of each primer, Ready Mix Taq Polymerase with MgCl₂ (Sigma, St. Louis, Mo.), sterile water to 50 μL total volume. The initial PCR cycling parameters were: a heat start at 95° C. for 8 minutes, followed by 30 cycles of 94° C. for 30 seconds, 55° C. for 30 seconds, 72° C. for 40 seconds, and finished with a cycle ay 72° C. for 5 minutes. The PCR reaction was performed in a PE Applied Biosystems Gene Amp PCR System 9700.

Gel purifies PCR products were used as template in second round of PCR to generate the final 307 bp product containing the A to G single point mutation. The PCR reaction mix for this second round of amplification was: product from initial PCR used as template—30-50 ng of each purified fragment, 50 ng of each primer, Ready Mix Taq Polymerase with MgCl₂ (Sigma, St. Louis, Mo.), sterile water to 50 μL total volume. PCR cycling parameters were: a heat start at 95° C. for 8 minutes, followed by 30 cycles of 94° C. for 30 seconds, 55° C. for 30 seconds, 72° C. for 40 seconds, and finished with a cycle ay 72° C. for 5 minutes. The final fragment with the correct A to G mutation was cloned into pCR4Blunt-TOPO vector (Invitrogen, Carlsbad, Calif.) and sequenced prior to cloning into pAV0201 vector via TaKara DNA Ligation protocol. The final plasmid was 2725 bp and included the expression cassette.

During construction of this plasmid, a new mutation at position 1620 bp which changed a “G” to an “A” was introduced in the origin of replication, affecting RNA II polymerase activity. This particular mutation boosted the plasmid yield by 28% versus the parental backbone, 4.1 mg/L versus 3.2 mg/L of culture.

The newly built plasmid backbone is multifunctional and was further used clone in the cDNA of the porcine wild-type GHRH, to generate plasmid “pAV0225”. Briefly, the porcine wild-type GHRH cDNA was inserted into the NcoI/HindIII site of the pAV0224 backbone, replacing the NcoI/HindIII fragment of HV-GHRH, to generate pAV0225 (SEQ ID NO.: 13). This new plasmid was 2721 bp in length.

In an effort to further render the plasmid backbone smaller, we used the “sir_graph” web application by Stewart and Zuker to predict the RNA II polymerase folding in the context of our plasmid (Zuker, 2003). We identified that a 163 bp fragment at the 3′end of the origin of replication could be deleted, without negatively impacting the functionality of the origin of replication. From pAV0225, we deleted the AflIII/Acc65I region of the pUC ori 3′end which also contains the T3 promoter, to generate the new plasmid described as “pAV0237” (SEQ ID NO.: 14). This newly produced plasmid was only 2558 bp, while fully functional.

EXAMPLE 3 New Versatile Optimized Plasmid Backbone “pAV0242”

A 53 bp deletion was made between the BglII and SacI sites of the pAV0237 plasmid to yield the new “pAV0242” (SEQ ID NO.: 15) plasmid that is 2505 bp while still including the GHRH coding sequence. The region deleted contained extraneous bacterial nucleotide sequence from the T7 promoter and some E. coli LacZ coding region. Removal of these sequences resulted in a plasmid 30% smaller than pAV0125, and 8% smaller than pAV0201, thus having the capacity to accommodate larger transgenes or cDNA fragments, while increasing plasmid yields and integrity.

Methods—Plasmid Construct—The plasmid “pAV0242” was synthesized by cloning in a synthetic 145 bp fragment into the BglII/SacI sites of pAV0237, while deleting the existing fragment. The synthetic BglII/SacI fragment had the 53 bp deletion (SEQ ID NO.: 16). The remainder of the plasmid was unchanged—SPc5-12 synthetic promoter, human 5′untranslated (5′UTR) region followed by porcine GHRH coding sequence and the 3′untranslated region and poly(A) signal of the human GH gene.

EXAMPLE 4 RNA II Promoter Mutations and Origin of Replication Optimization

RNA II is stimulating replication of ColE1-derived plasmids which is inhibited by RNA I. Increasing the RNA II to RNA I ratio should increase the frequency of DNA replication initiation events, which should yield higher plasmid copy number. The danger is the production of levels of RNA II that are so elevated that they would lead to “runaway” plasmid replication. Thus, strict control of the relative potency of these sequences is necessary. By introducing targeted substitutions in the bacterial origin of replication, one can increase plasmid yield and decrease fermentation time, thus increasing productivity.

Two rounds of PCR were used to generate the mutations in the RNA II promoter regions. The initial PCR primers contain the desired mutations in both the forward and reverse sequence. All primers were synthesized by Sigma Aldrich, The Woodlands, Tex. The forward (upper) primers (included below) were run with the NheI primer to generate an approximate 90 bp band. The reverse (lower) primers were run with the AlwNI primer to generate an approximate 250 bp band. The PCR reaction mix was separated by electrophoresis and the 90 bp and 250 bp bands were gel purified using the StrataPrep DNA Gel Extraction Kit (Stratagene, La Jolla, Calif.) and the product used as template in the second PCR. AlwNI and NheI primers were used in the second round of PCR to generate a final 272 bp fragment. These fragments were cloned to replace the existing fragment in the origin of replication, and generate the “ori” high yield mutants. In all cases 44 ng of template were used for the second PCR reaction. Only mutations that had at least the same growth characteristics as the parental pAV0242 were included in this application. While a larger number of mutants were screened, some mutations resulted in plasmids that could not grow under standard conditions, proving that some mutations in the origin of replication can be detrimental.

Wild-Type

Gtttttttgtttacaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttg atcttttc—this sequence is contained within the origin of replication sequence (SEQ ID NO.: 11). An example of this sequence in a plasmid can be found in the Ori of (SEQ ID NOs.: 12, 13, 14, and 15).

Mutant 1

gtttttttgtttacaagcagcatattacgcgcagaaaaaaaggatctcaagaagatcctttgat cttttc—this sequence is contained within the origin of replication designated as “mut 1” (SEQ ID NO.: 37). An example of this sequence in a plasmid can be found in the Ori of (SEQ ID NO.: 31).

Mutant 2

Gttttttgtttacaagcagcagtttacgcgcagaaaaaaaggatctcaagaagatcctttga tcttttc—this sequence is contained within the origin of replication designated as “mut 2” (SEQ ID NO.: 38). An example of this sequence in a plasmid can be found in the Ori of (SEQ ID NO.: 32)

Mutant 3

Gtttttttgtttacaagcagcagaatacgcgcagaaaaaaaggatctcaagaagatcctttg atcttttc—this sequence is contained within the origin of replication designated as “mut 3” (SEQ ID NO.: 39). An example of this sequence in a plasmid can be found in the Ori of (SEQ ID NO.: 33)

Mutant 8

gtttttttgtttacaagcagcattttacgcgcagaaaaaaaggatctcaagaagatcctttgatc ttttc—this sequence is contained within the origin of replication designated as “mut 8” (SEQ ID NO.: 40). An example of this sequence in a plasmid can be found in the Ori of (SEQ ID NO.: 34)

Mutant 9

gtttttttgacaagcagcataatacgcgcagaaaaaaaggatctcaagaagatcctttga tcttttc—this sequence is contained within the origin of replication designated as “mut 9” (SEQ ID NO.: 41). An example of this sequence in a plasmid can be found in the Ori of (SEQ ID NO.: 35)

Primer sequence: Mutation 1—to generate this G to T mutation at position −9 in the RNAII promoter the following set of primers was used: forward 5′GCAGCATATTACGCGCAG 3′ and reverse 5′CTGCGCGTAATATGCTGC 3′. The initial PCR cycling parameters were: a heat start at 95° C. for 8 minutes, followed by 30 cycles of 94° C. for 30 seconds, 53° C. for 30 seconds, 72° C. for 40 seconds, and finished with a cycle ay 72° C. for 5 minutes. The second PCR parameters were: a heat start at 95° C. for 8 minutes followed by 30 cycles of 94° C. for 30 seconds, 55° C. for 30 seconds, 72° C. for 40 seconds, and finished with a cycle ay 72° C. for 5 minutes.

Primer sequence: Mutation 2—to generate this A to T mutation at −10 in the RNAII promoter the following set of primers was used: forward 5′GCAGCAGTTTACGCGCAG 3′ and reverse 5′GCGCGTAAACTGCTGCTTG 3′. The initial PCR cycling parameters were: a heat start at 95° C. for 8 minutes, followed by 30 cycles of 94° C. for 30 seconds, 64° C. for 30 seconds, 72° C. for 40 seconds, and finished with a cycle ay 72° C. for 5 minutes. The second PCR parameters were: a heat start at 95° C. for 8 minutes followed by 30 cycles of 94° C. for 30 seconds, 55° C. for 30 seconds, 72° C. for 40 seconds, and finished with a cycle ay 72° C. for 5 minutes.

Primer sequence: Mutation 3—to generate this T to A mutation at −11 in the RNAII promoter the following set of primers was used: forward 5′GCAGCAGAATACGCGCAG 3′ and reverse 5′GCGCGTATTCTGCTGCTTG 3′. The initial PCR cycling parameters were: a heat start at 95° C. for 8 minutes, followed by 30 cycles of 94° C. for 30 seconds, 64° C. for 30 seconds, 72° C. for 40 seconds, and finished with a cycle ay 72° C. for 5 minutes. The second PCR parameters were: a heat start at 95° C. for 8 minutes followed by 30 cycles of 94° C. for 30 seconds, 55° C. for 30 seconds, 72° C. for 40 seconds, and finished with a cycle ay 72° C. for 5 minutes.

Primer sequence: Mutation 8—to generate this G to T mutation at −9 and A to T mutation at −10 in the RNAII promoter the following set of primers was used: forward 5′CAAGCAGCATTTTACGCGCAG3′ and reverse 5′CTGCGCGTAAAATGCTGCTTG3′. The initial PCR cycling parameters were: a heat start at 95° C. for 8 minutes, followed by 30 cycles of 94° C. for 30 seconds, 56° C. for 30 seconds, 72° C. for 40 seconds, and finished with a cycle ay 72° C. for 5 minutes. The second PCR parameters were: a heat start at 95° C. for 8 minutes followed by 30 cycles of 94° C. for 30 seconds, 55° C. for 30 seconds, 72° C. for 40 seconds, and finished with a cycle ay 72° C. for 5 minutes.

Primer sequence: Mutation 9—to generate this G to T mutation at −9 and T to A mutation at −11 in the RNAII promoter the following set of primers was used: forward 5′CAAGCAGCATAATACGCGCAG3′ and reverse 5′CTGCGCGTATTATGCTGCTTG3′. The initial PCR cycling parameters were: a heat start at 95° C. for 8 minutes, followed by 30 cycles of 94° C. for 30 seconds, 56° C. for 30 seconds, 72° C. for 40 seconds, and finished with a cycle ay 72° C. for 5 minutes. The second PCR parameters were: a heat start at 95° C. for 8 minutes followed by 30 cycles of 94° C. for 30 seconds, 55° C. for 30 seconds, 72° C. for 40 seconds, and finished with a cycle ay 72° C. for 5 minutes.

Primer sequence: AlwNI universal forward primer had the following sequence: 5′GCAGCAGCCACTGGTAACAGGATTAG3′

Primer sequence: NheI universal reverse primer had the following sequence: 5′CGAGTTCTTCTGAGCGCTAGCTGAG3′

Fragments determined to have the correct sequence were cloned into the AlwNI/Nhe site of pAV0242 to generate the new family of plasmids “mut”. Briefly, the pAV0242 plasmid and correct mini-prep DNA were digested with AlwNI and Nhe I enzymes (NEB, Beverly, Mass.) to generate the vector and insert fragments for ligation. The fragments were gel purified with StrataPrep DNA Gel Extraction Kit (Stratagene, La Jolla, Calif.). The vector was dephosphorylated with Antarctic Phosphatase (NEB, Beverly, Mass.) and the ligation was carried out with TaKara's DNA Ligation Kit (TaKara Mirus Bio. Inc., Madison, Wis.).

Aliquots of 1 or 3 μL of each ligation was plated on at least three different LB/agar plates with 50 μg/mL kanamycin, and incubated over-night at 37° C. The number of colonies on each plate was counted the next day, and the average number of colonies is given (FIG. 7). The number of colonies generated was similar between all groups, with the exception of mutant 1 that had significantly lowed average number of colonies per plate, indicator of poor growth and performance under selection conditions.

The effectiveness and results of combination of mutations was unpredictable, and was assessed only after the sequence was synthetically generated and tested. As a proof, we have designed and tested some 10 other mutants that would have changed the −35 sequence present in the pUC plasmids “TTGAGA” to the consensus sequence “TTGACA” described in numerous other plasmids. In all this cases, 0 to 3 colonies were obtained on each plate, and no growth of the transformed bacteria was observed under selection conditions. We thus concluded that under the sequence/structure present in our plasmids, changes to the −35 element are detrimental.

Growth studies were performed to determine plasmid yields. All 5 plasmids with mutations in the RNAII promote were diluted to 10 ng/μL. Equal amounts were used to transform competent E. coli DH5α's. Different amounts of the transformation reaction were plated in triplicate and colony counts were done on each plate to give an average number of colonies per plasmid. From these plates, colonies were picked for overnight cultures in 5 mL of growth media. From these cultures, 100 mL of LB broth/kanamycin was inoculated with 100 μL of overnight culture, in duplicate. Timed optical density readings were taken at 4, 5, 6, 7, 8, 9, 11 and 13 hours to generate a growth curve (see FIG. 8). As depicted in FIGS. 8A and 8B, all the mutants had better growth patterns after 13 hours of fermentation than the pAV0242, the parental backbone.

The remaining culture volume was used to isolate plasmid DNA to determine estimates for plasmid yield using procedures described in the manufacturer's manual for Stratagene mini-prep kit (Stratagene, La Jolla, Calif.) (3 mL culture volume) or Qiagen midi-prep kit (Qiagen, Valencia, Calif.) (45 mL culture volume). Average plasmid yield from the midi-prep purifications are given in FIG. 9. As shown, plasmids containing origin of replication with mutations 3 and 8 gave better plasmids yield (8.3 and 5%, respectively) when compared to the parental backbone pAV0242. FIG. 10 shows similar results when giga-preps (similar to large-scale fermentation) are employed—plasmids containing the origin of replication “mut 3” gave a 30% increase in plasmid yield, while plasmids containing the origin of replication “mut 8” gave a 42% increase in plasmid yield.

The above optimized plasmid constructs can be administered to a mammalian host for various therapeutic effects. One skilled in the art recognizes that different methods of delivery may be utilized to administer an optimized synthetic expression vector into a cell. Examples include: (1) methods utilizing physical means, such as electroporation (electricity), a gene gun (physical force) or applying large volumes of a liquid (pressure); and (2) methods wherein said vector is complexed to another entity, such as a liposome or a transporter molecule.

Accordingly, the present invention provides a method of creating plasmids with small optimized backbones capable of accommodating large transgenes, with increased plasmid yields and decreased fermentation times, which ultimately can be transferring a therapeutic gene to a host, which comprises administering the vector of the present invention, preferably as part of a composition, using any of the aforementioned routes of administration or alternative routes known to those skilled in the art and appropriate for a particular application. Effective gene transfer of a vector to a host cell in accordance with the present invention to a host cell can be monitored in terms of a therapeutic effect (e.g. alleviation of some symptom associated with the particular disease being treated) or, further, by evidence of the transferred gene or expression of the gene within the host (e.g., using the polymerase chain reaction in conjunction with sequencing, Northern or Southern hybridizations, or transcription assays to detect the nucleic acid in host cells, or using immunoblot analysis, antibody-mediated detection, mRNA or protein half-life studies, or particularized assays to detect protein or polypeptide encoded by the transferred nucleic acid, or impacted in level or function due to such transfer).

These compositions and methods described herein are by no means all-inclusive, and further methods to suit the specific application will be apparent to the ordinary skilled artisan. Moreover, the effective amount of the compositions can be further approximated through analogy to compounds known to exert the desired effect.

REFERENCES CITED

The entire content of each of the following U.S. patent, foreign patent and publication documents is incorporated by reference herein.

-   Australian Patent 772,752 titled “SUPER PORCINE GROWTH HORMONE     RELEASING HORMONE ANALOG,” issued on Aug. 20, 2004. -   Australian Patent 770,982 titled “IGF-1 EXPRESSION SYSTEM AND     METHODS OF USE,” issued on Jun. 24, 2004 -   U.S. Pat. No. 6,551,996 titled “SUPER-ACTIVE PORCINE GROWTH HORMONE     RELEASING HORMONE ANALOG,” issued on Apr. 22, 2003. -   U.S. Pat. No. 5,374,544 titled “MUTATED SKELETAL ACTIN PROMOTER,”     issued on Dec. 20, 1994. -   U.S. Pat. No. 6,423,693 titled “GROWTH HORMONE RELEASING HORMONE     EXPRESSION SYSTEM AND METHODS OF USE, INCLUDING USE IN ANIMALS,     issued on Jul. 23, 2002 -   U.S. Pat. No. 6,410,228 titled “METHOD FOR THE IDENTIFICATION OF     SYNTHETIC CELL-OR-TISSUE-SPECIFIC TRANSCRIPTIONAL REGULATORY     REGIONS,” issued on Jun. 25, 2002. -   U.S. Pat. No. 5,298,422, titled “MYOGENIC VECTOR SYSTEMS,” issued on     Mar. 29, 1994. -   U.S. Pat. No. 5,756,264, titled “MYOGENIC VECTOR SYSTEMS,” issued on     May 26, 1998. -   U.S. Pat. No. 5,925,564 titled “MYOGENIC VECTOR SYSTEMS,” issued on     Jul. 20, 1999. -   U.S. Pat. No. 5,364,791 titled “PROGESTERONE RECEPTOR HAVING C.     TERMINAL HORMONE BINDING DOMAIN TRUNCATIONS,” issued on Nov. 15,     1994. -   U.S. Pat. No. 5,874,534 titled “PROGESTERONE RECEPTOR HAVING C.     TERMINAL HORMONE BINDING DOMAIN TRUNCATIONS,” issued on Feb. 23,     1999. -   U.S. Pat. No. 5,935,934 titled “PROGESTERONE RECEPTOR HAVING C.     TERMINAL HORMONE BINDING DOMAIN TRUNCATIONS,” issued on Aug. 10,     1999. -   U.S. Pat. No. 6,040,295 titled “FORMULATED NUCLEIC ACID COMPOSITIONS     AND METHODS OF ADMINISTERING THE SAME FOR GENE THERAPY,” issued on     Mar. 21, 2000. -   U.S. Pat. No. 4,822,470 titled “METHOD OF AND APPARATUS FOR CELL     PORATION AND CELL FUSION USING RADIOFREQUENCY ELECTRICAL PULSES,”     issued on Apr. 18, 1989. -   U.S. Pat. No. 4,970,154 titled “METHOD OF AND APPARATUS FOR CELL     PORATION AND CELL FUSION USING RADIOFREQUENCY ELECTRICAL PULSES,”     issued on Nov. 13, 1990. -   U.S. Pat. No. 5,304,486 titled “METHOD OF AND APPARATUS FOR CELL     PORATION AND CELL FUSION USING RADIOFREQUENCY ELECTRICAL PULSES,”     issued on Apr. 19, 1994. -   U.S. Pat. No. 6,551,996 issued on Apr. 23, 2003 and titled “SUPER     ACTIVE PORCINE GROWTH HORMONE RELEASING HORMONE ANALOG,” with     Schwartz, et al., listed as inventors. -   U.S. Pat. No. 6,114,148 issued on Sep. 5, 2000 and titled “HIGH     LEVEL EXPRESSION OF PROTEINS,” with Seed, et al., listed as     inventors. -   U.S. Pat. No. 5,292,721 issued on Mar. 8, 1994 and titled “USE OF     GROWTH HORMONE TO ENHANCE PORCINE FETAL ENERGY AND SOW LACTATION     PERFORMANCE,” with Boyd, et al., listed as inventors. -   U.S. Pat. No. 5,134,120 issued on Jul. 28, 1992 and titled “USE OF     GROWTH HORMONE TO ENHANCE PORCINE WEIGHT GAIN,” with Boyd, et al.,     listed as inventors. -   U.S. Pat. No. 5,061,690 issued on Oct. 29, 1991 and titled “METHOD     FOR INCREASING MILK PRODUCTION IN MAMMALS AND/OR INCREASING THE     BIRTH WEIGHT OF THEIR NEWBORN AND IMPROVING POSTNATAL GROWTH,” with     Kann, et al., listed as inventors. -   U.S. patent application Ser. No. 10/237,146 Titled “LINEAR DNA     FRAGMENTS FOR GENE EXPRESSION” filed on Sep. 6, 2002. -   U.S. patent application Ser. No. 10/021,403 Titled “ADMINISTRATION     OF NUCLEIC ACID SEQUENCE TO FEMALE ANIMAL TO ENHANCE GROWTH IN     OFFSPRING,” filed on Dec. 12, 2001. -   U.S. patent application Ser. No. 10/281,067 titled “A COMPOSITION     AND METHOD TO ALTER LEAN BODY MASS AND BONE PROPERTIES IN A     SUBJECT,” filed on Oct. 25, 2002. -   U.S. patent application Ser. No. 10/315,907 titled “PLASMID MEDIATED     SUPPLEMENTATION FOR TREATING CHRONICALLY ILL SUBJECTS,” filed on     Dec. 10, 2002. -   U.S. patent application Ser. No. 10/359,919 titled “MODIFIED     PITUITARY GLAND DEVELOPMENT IN OFFSPRING FROM EXPECTANT MOTHER     ANIMALS TREATED WITH GROWTH HORMONE RELEASING HORMONE THERAPY,”     filed on Feb. 6, 2003. -   U.S. patent application Ser. No. 10/360,768 titled “ELECTRODE     ASSEMBLY FOR CONSTANT-CURRENT ELECTROPORATION AND USE,” filed on     Mar. 7, 2002. -   U.S. patent application Ser. No. 10/657,725 titled “ELECTRODE     ASSEMBLY FOR CONSTANT-CURRENT ELECTROPORATION AND USE,” filed on     Sep. 8, 2003. -   U.S. patent application Ser. No. 10/395,709 titled “INCREASED     DELIVERY OF A NUCLEIC ACID CONSTRUCT IN VIVO BY THE POLY-L-GLUTAMATE     (“PLG”) SYSTEM,” filed on Mar. 24, 2003. -   U.S. patent application Ser. No. 10/619,939 titled “CODON OPTIMIZED     SYNTHETIC PLASMIDS,” filed on Jul. 15, 2003. -   U.S. patent application Ser. No. 10/166,356 titled “PROTEASE     RESISTANT TI-GROWTH HORMONE RELEASING HORMONE (“GHRH”),” filed on     Aug. 21, 2002. -   U.S. patent application Ser. No. 10/699,597 titled “SYNTHETIC MUSCLE     PROMOTERS WITH ACTIVITIES EXCEEDING NATURALLY OCCURRING REGULATORY     SEQUENCES IN CARDIAC CELLS,” filed on Oct. 30, 2003. -   U.S. patent application Ser. No. 10/764,818 titled “REDUCING CULLING     1N HERD ANIMALS GROWTH HORMONE RELEASING HORMONE (GHRH),” filed on     Jan. 26, 2004. -   U.S. patent application Ser. No. 10/798,896 titled “INSULIN-LIKE     GROWTH FACTOR (IGF-1) PLASMID-MEDIATED SUPPLEMENTATION FOR     THERAPEUTIC APPLICATIONS,” filed on Mar. 11, 2004. -   U.S. patent application Ser. No. 10/827,918, titled “PLASMID     MEDIATED GHRH SUPPLEMENTATION FOR RENAL FAILURES,” filed on Apr. 20,     2004. -   U.S. patent application Ser. No. 10/857,439 titled “DEVICES AND     METHODS FOR BIOMATERIAL PRODUCTION,” filed on May 27, 2004. -   U.S. patent application Ser. No. 10/894,644 titled “CANINE-SPECIFIC     GROWTH HORMONE RELEASING HORMONE,” filed on Jul. 20, 2004. -   U.S. patent application Ser. No. 11/015,935 titled “REDUCING     ARTHRITIS AND LAMENESS 1N SUBJECTS BY GROWTH HORMONE RELEASING     HORMONE (“GHRH”) SUPPLEMENTATION,” filed on Dec. 17, 2004. -   United States Patent Application TBA, titled “ENHANCED     SECRETION/RETENTION OF GROWTH HORMONE RELEASING HORMONE (GHRH) FROM     MUSCLE CELLS BY SPECIES-SPECIFIC SIGNAL PEPTIDE, Attorney Docket     Number (108328.0249). -   U.S. Patent Application 60/590,739 Titled “GROWTH HORMONE RELEASING     HORMONE ENHANCES VACCINATION RESPONSE, filed on Jul. 23, 2004.

NON-PATENT REFERENCE LIST

-   Acsadi, G., G. Dickson, D. R. Love, A. Jani, F. S. Walsh, A.     Gurusinghe, Wolff, J A, and K. E. Davies. 1991. Human dystrophin     expression in mdx mice after intramuscular injection of DNA     constructs. Nature 352:815-818. -   Aihara, H. and J. Miyazaki. 1998. Gene transfer into muscle by     electroporation in vivo. Nat. Biotechnol. 16:867-870. -   Almendro, N., T. Bellon, C. Rius, P. Lastres, C. Langa, A. Corbi,     and C. Bemabeu. 1996. Cloning of the human platelet endothelial cell     adhesion molecule-1 promoter and its tissue-specific expression.     Structural and functional characterization. J. Immunol.     157:5411-5421. -   Aratani, Y., R. Okazaki, and H. Koyama. 1992. End extension repair     of introduced targeting vectors mediated by homologous recombination     in mammalian cells. Nucleic Acids Res. 20:4795-4801. -   Babiuk, L. A., R. Pontarollo, S. Babiuk, B. Loehr, and van Drunen     Littel-van den Hurk. 2003. Induction of immune responses by DNA     vaccines in large animals. Vaccine 21:649-658. -   Bert, A. G., J. Burrows, C. S. Osborne, and P. N. Cockerill. 2000.     Generation of an improved luciferase reporter gene plasmid that     employs a novel mechanism for high-copy replication. Plasmid     44:173-182. -   Bettan, M., F. Emmanuel, R. Darteil, J. M. Caillaud, F. Soubrier, P.     Delaere, D. Branelec, A. Mahfoudi, N. Duverger, and D.     Scherman. 2000. High-level protein secretion into blood circulation     after electric pulse-mediated gene transfer into skeletal muscle.     Mol. Ther. 2:204-210. -   Boshart, M., F. Weber, G. Jahn, K. Dorsch-Hasler, B. Fleckenstein,     and W. Schaffner. 1985. A very strong enhancer is located upstream     of an immediate early gene of human cytomegalovirus. Cell     41:521-530. -   Brown, P. A., W. C. Davis, and R. Draghia-Akli. 2004. Immune     enhancing effects of growth hormone releasing hormone delivered by     plasmid injection and electroporation. Molecular Therapy 10:644-651. -   Bujard, H., C. Baldari, M. Brunner, U. Deuschle, R. Gentz, J.     Hughes, W. Kammerer, and D. Stuber. 1983. Integration of efficient     promoters of the E. coli system into plasmid vectors. Gene Amplif.     Anal. 3:65-87.:65-87. -   Carbonelli, D. L., E. Corley, M. Seigelchifer, and J.     Zorzopulos. 1999. A plasmid vector for isolation of strong promoters     in Escherichia coli. FEMS Microbiol. Lett. 177:75-82. -   Chandler, S. D., A. Mayeda, J. M. Yeakley, A. R. Krainer, and X. D.     Fu. 1997. RNA splicing specificity determined by the coordinated     action of RNA recognition motifs in SR proteins. Proc. Natl. Acad.     Sci. U.S. A 94:3596-3601. -   Cocea, L. 1997. Duplication of a region in the multiple cloning site     of a plasmid vector to enhance cloning-mediated addition of     restriction sites to a DNA fragment. Biotechniques 23:814-816. -   Dai, B., H. Wu, E. Holthuizen, and P. Singh. 2001. Identification of     a novel cis element required for cell density-dependent     down-regulation of insulin-like growth factor-2 P3 promoter activity     in Caco2 cells. J. Biol. Chem. 276:6937-6944. -   Danko, I. and J. A. Wolff. 1994. Direct gene transfer into muscle.     [Review]. Vaccine 12:1499-1502. -   Darquet, A. M., B. Cameron, P. Wils, D. Scherman, and J.     Crouzet. 1997. A new DNA vehicle for nonviral gene delivery:     supercoiled minicircle. Gene Ther. 4:1341-1349. -   Darquet, A. M., R. Rangara, P. Kreiss, B. Schwartz, S. Naimi, P.     Delaere, J. Crouzet, and D. Scherman. 1999. Minicircle: an improved     DNA molecule for in vitro and in vivo gene transfer. Gene Ther.     6:209-218. -   Dasgupta, S., H. Masukata, and J. Tomizawa. 1987. Multiple     mechanisms for initiation of ColE1 DNA replication: DNA synthesis in     the presence and absence of ribonuclease H. Cell 51:1113-1122. -   Davis, H. L., R. G. Whalen, and B. A. Demeneix. 1993. Direct gene     transfer into skeletal muscle in vivo: factors affecting efficiency     of transfer and stability of expression. Human Gene Therapy     4:151-159. -   Deuschle, U., W. Kammerer, R. Gentz, and H. Bujard. 1986. Promoters     of Escherichia coli: a hierarchy of in vivo strength indicates     alternate structures. EMBO J. 5:2987-2994. -   Dolnik, V., M. Novotny, and J. Chmelik. 1993. Electromigration     behavior of poly-(L-glutamate) conformers in concentrated     polyacrylamide gels. Biopolymers 33:1299-1306. -   Dorsch-Hasler, K., G. M. Keil, F. Weber, M. Jasin, W. Schaffner,     and U. H. Koszinowski. 1985. A long and complex enhancer activates     transcription of the gene coding for the highly abundant immediate     early mRNA in murine cytomegalovirus. Proc. Natl. Acad. Sci. U.S. A     82:8325-8329. -   Draghia-Akli, R., K. M. Ellis, L. A. Hill, P. B. Malone, and M. L.     Fiorotto. 2003. High-efficiency growth hormone releasing hormone     plasmid vector administration into skeletal muscle mediated by     electroporation in pigs. FASEB J 17:526-528. -   Draghia-Akli, R., M. L. Fiorotto, L. A. Hill, P. B. Malone, D. R.     Deaver, and R. J. Schwartz. 1999. Myogenic expression of an     injectable protease-resistant growth hormone-releasing hormone     augments long-term growth in pigs. Nat. Biotechnol. 17:1179-1183. -   Draghia-Akli, R., K. A. Hahn, G. K. King, K. Cummings, and R. H.     Carpenter. 2002a. Effects Of Plasmid Mediated Growth Hormone     Releasing Hormone In Severely Debilitated Dogs With Cancer.     Molecular Therapy 6:830-836. -   Draghia-Akli, R., A. S. Khan, K. K. Cummings, D. Parghi, R. H.     Carpenter, and P. A. Brown. 2002b. Electrical Enhancement of     Formulated Plasmid Delivery in Animals. Technology in Cancer     Research & Treatment 1:365-371. -   Draghia-Akli, R., X. G. Li, and R. J. Schwartz. 1997. Enhanced     growth by ectopic expression of growth hormone releasing hormone     using an injectable myogenic vector. Nat. Biotechnol. 15:1285-1289. -   Draghia-Akli, R., P. B. Malone, L. A. Hill, K. M. Ellis, R. J.     Schwartz, and J. L. Nordstrom. 2002c. Enhanced animal growth via     ligand-regulated GHRH myogenic-injectable vectors. FASEB J.     16:426-428. -   Fewell, J. G., F. MacLaughlin, V. Mehta, M. Gondo, F. Nicol, E.     Wilson, and L. C. Smith. 2001. Gene therapy for the treatment of     hemophilia B using PINC-formulated plasmid delivered to muscle with     electroporation. Mol. Ther. 3:574-583. -   Frederickson, R. M., B. J. Carter, and A. M. Pilaro. 2003.     Nonclinical Toxicology in Support of Licensure of Gene Therapies.     Mol. Ther. 8:8-10. -   Fryer, A. D. and D. B. Jacoby. 1993. Effect of inflammatory cell     mediators on M2 muscarinic receptors in the lungs. Life Sci.     52:529-536. -   Gayle, R. B., III, P. S. Vermersch, and G. N. Bennett. 1986.     Construction and characterization of pBR322-derived plasmids with     deletions of the RNA I region. Gene 41:281-288. -   Gehl, J., T. Skovsgaard, and L. M. Mir. 1998. Enhancement of     cytotoxicity by electropermeabilization: an improved method for     screening drugs. Anticancer Drugs 9:319-325. -   Gehl, J., T. H. Sorensen, K. Nielsen, P. Raskmark, S. L. Nielsen, T.     Skovsgaard, and L. M. Mir. 1999. In vivo electroporation of skeletal     muscle: threshold, efficacy and relation to electric field     distribution. Biochim. Biophys. Acta 1428:233-240. -   German, M., S. Ashcroft, K. Docherty, H. Edlund, T. Edlund, S.     Goodison, H. Imura, G. Kennedy, O. Madsen, D. Melloul, and 1995. The     insulin gene promoter. A simplified nomenclature. Diabetes     44:1002-1004. -   Harley, C. B. and R. P. Reynolds. 1987. Analysis of E. coli promoter     sequences. Nucleic Acids Res. 15:2343-2361. -   Heller, R., M. J. Jaroszeski, L. F. Glass, J. L. Messina, D. P.     Rapaport, R. C. DeConti, N. A. Fenske, R. A. Gilbert, L. M. Mir,     and D. S. Reintgen. 1996. Phase I/II trial for the treatment of     cutaneous and subcutaneous tumors using electrochemotherapy. Cancer     77:964-971. -   Horlick, R. A. and P. A. Benfield. 1989. The upstream     muscle-specific enhancer of the rat muscle creatine kinase gene is     composed of multiple elements. Mol. Cell Biol. 9:2396-2413. -   Inouye, C., P. Remondelli, M. Karin, and S. Elledge. 1994. Isolation     of a cDNA encoding a metal response element binding protein using a     novel expression cloning procedure: the one hybrid system. DNA Cell     Biol. 13:731-742. -   Inouye, S., A. Nakazawa, and T. Nakazawa. 1985. Determination of the     transcription initiation site and identification of the protein     product of the regulatory gene xylR for xyl operons on the TOL     plasmid. J. Bacteriol. 163:863-869. -   Jaynes, J. B., J. E. Johnson, J. N. Buskin, C. L. Gartside,     and S. D. Hauschka. 1988. The muscle creatine kinase gene is     regulated by multiple upstream elements, including a muscle-specific     enhancer. Mol. Cell Biol. 8:62-70. -   Jenkins, G. J., H. S. Suzen, R. A. Sueiro, and J. M. Parry. 1999.     The restriction site mutation assay: a review of the methodology     development and the current status of the technique. Mutagenesis     14:439-448. -   Kammerer, W., U. Deuschle, R. Gentz, and H. Bujard. 1986. Functional     dissection of Escherichia coli promoters: information in the     transcribed region is involved in late steps of the overall process.     EMBO J. 5:2995-3000. -   Kawamoto, T., K. Makino, H. Niwa, H. Sugiyama, S. Kimura, M.     Amemura, A. Nakata, and T. Kakunaga. 1988. Identification of the     human beta-actin enhancer and its binding factor. Mol. Cell Biol.     8:267-272. -   Kawamoto, T., K. Makino, S. Orita, A. Nakata, and T. Kakunaga. 1989.     DNA bending and binding factors of the human beta-actin promoter.     Nucleic Acids Res. 17:523-537. -   Klamut, H. J., L. O. Bosnoyan-Collins, R. G. Worton, P. N. Ray,     and H. L. Davis. 1996. Identification of a transcriptional enhancer     within muscle intron I of the human dystrophin gene. Hum. Mol.     Genet. 5:1599-1606. -   Klamut, H. J., S. B. Gangopadhyay, R. G. Worton, and P. N.     Ray. 1990. Molecular and functional analysis of the muscle-specific     promoter region of the Duchenne muscular dystrophy gene. Mol. Cell     Biol. 10:193-205. -   Kraus, J., M. Woltje, N. Schonwetter, and V. Hollt. 1998.     Alternative promoter usage and tissue specific expression of the     mouse somatostatin receptor 2 gene. FEBS Lett. 428:165-170. -   Lahijani, R., G. Hulley, G. Soriano, N. A. Horn, and M.     Marquet. 1996. High-yield production of pBR322-derived plasmids     intended for human gene therapy by employing a     temperature-controllable point mutation. Hum. Gene Ther. %20;7:     1971-1980. -   Lareyre, J. J., T. Z. Thomas, W. L. Zheng, S. Kasper, D. E.     Ong, M. C. Orgebin-Crist, and R. J. Matusik. 1999. A 5-kilobase pair     promoter fragment of the murine epididymal retinoic acid-binding     protein gene drives the tissue-specific, cell-specific, and     androgen-regulated expression of a foreign gene in the epididymis of     transgenic mice. J. Biol. Chem. 274:8282-8290. -   Larsen, P. R., J. W. Harney, and D. D. Moore. 1986. Sequences     required for cell-type specific thyroid hormone regulation of rat     growth hormone promoter activity. J. Biol. Chem. 261:14373-14376. -   Ledwith, B. J., S. Manam, P. J. Troilo, A. B. Barnum, C. J.     Pauley, T. G. Griffiths, L. B. Harper, C. M. Beare, W. J. Bagdon,     and W. W. Nichols. 2000a. Plasmid DNA vaccines: investigation of     integration into host cellular DNA following intramuscular injection     in mice. Intervirology 43:258-272. -   Ledwith, B. J., S. Manam, P. J. Troilo, A. B. Barnum, C. J.     Pauley, T. G. Griffiths, L. B. Harper, H. B. Schock, H. Zhang, J. E.     Faris, P. A. Way, C. M. Beare, W. J. Bagdon, and W. W. Nichols.     2000b. Plasmid DNA vaccines: assay for integration into host genomic     DNA. Dev. Biol. (Basel) 104:33-43.:33-43. -   Lee, S. H., W. Wang, S. Yajima, P. A. Jose, and M. M.     Mouradian. 1997. Tissue-specific promoter usage in the D1A dopamine     receptor gene in brain and kidney. DNA Cell Biol. 16:1267-1275. -   Lesbordes, J. C., T. Bordet, G. Haase, L. Castelnau-Ptakhine, S.     Rouhani, H. Gilgenkrantz, and A. Kahn. 2002. In vivo electrotransfer     of the cardiotrophin-1 gene into skeletal muscle slows down     progression of motor neuron degeneration in pmn mice. Hum. Mol.     Genet. 11:1615-1625. -   Levenson, V. V., E. D. Transue, and I. B. Roninson. 1998. Internal     ribosomal entry site-containing retroviral vectors with green     fluorescent protein and drug resistance markers. Hum. Gene Ther.     9:1233-1236. -   Li, C., S. Ke, Q. P. Wu, W. Tansey, N. Hunter, L. M. Buchmiller, L.     Milas, C. Charnsangavej, and S. Wallace. 2000. Tumor irradiation     enhances the tumor-specific distribution of poly(L-glutamic     acid)-conjugated paclitaxel and its antitumor efficacy. Clin. Cancer     Res. 6:2829-2834. -   Li, X., E. M. Eastman, R. J. Schwartz, and R. Draghia-Akli. 1999.     Synthetic muscle promoters: activities exceeding naturally occurring     regulatory sequences. Nat. Biotechnol. 17:241-245. -   Lin, H., K. E. Yutzey, and S. F. Konieczny. 1991. Muscle-specific     expression of the troponin I gene requires interactions between     helix-loop-helix muscle regulatory factors and ubiquitous     transcription factors. Mol. Cell Biol. 11:267-280. -   Lin-Chao, S., W. T. Chen, and T. T. Wong. 1992. High copy number of     the pUC plasmid results from a Rom/Rop-suppressible point mutation     in RNA II. Mol. Microbiol. 6:3385-3393. -   Liu, Y., H. Li, K. Tanaka, N. Tsumaki, and Y. Yamada. 2000.     Identification of an enhancer sequence within the first intron     required for cartilage-specific transcription of the alpha2(XI)     collagen gene. J. Biol. Chem. 275:12712-12718. -   Lucas, M. L., L. Heller, D. Coppola, and R. Heller. 2002. IL-12     plasmid delivery by in vivo electroporation for the successful     treatment of established subcutaneous B16.F10 melanoma. Mol. Ther.     5:668-675. -   Lucas, M. L., M. J. Jaroszeski, R. Gilbert, and R. Heller. 2001. In     vivo electroporation using an exponentially enhanced pulse: a new     waveform. DNA Cell Biol. 20:183-188. -   Lyons, A. J. and H. D. Robertson. 2003. Detection of tRNA-like     structure through RNase P cleavage of viral internal ribosome entry     site RNAs near the AUG start triplet. J. Biol. Chem.     278:26844-26850. -   Macejak, D. G. and P. Sarnow. 1991. Internal initiation of     translation mediated by the 5′ leader of a cellular mRNA. Nature     353:90-94. -   Manam, S., B. J. Ledwith, A. B. Barnum, P. J. Troilo, C. J.     Pauley, L. B. Harper, T. G. Griffiths, Z. Niu, L. Denisova, T. T.     Follmer, S. J. Pacchione, Z. Wang, C. M. Beare, W. J. Bagdon,     and W. W. Nichols. 2000. Plasmid DNA vaccines: tissue distribution     and effects of DNA sequence, adjuvants and delivery method on     integration into host DNA. Intervirology 43:273-281. -   Manders, P. and R. Thomas. 2000. Immunology of DNA vaccines: CpG     motifs and antigen presentation. Inflamm. Res. 49:199-205. -   Martineau, Y., C. Le Bec, L. Monbrun, V. Allo, I. M. Chiu, O.     Danos, H. Moine, H. Prats, and A. C. Prats. 2004. Internal ribosome     entry site structural motifs conserved among mammalian fibroblast     growth factor 1 alternatively spliced mRNAs. Mol. Cell Biol.     24:7622-7635. -   Matsubara, H., Y. Gunji, T. Maeda, K. Tasaki, Y. Koide, T. Asano, T.     Ochiai, S. Sakiyama, and M. Tagawa. 2001. Electroporation-mediated     transfer of cytokine genes into human esophageal tumors produces     anti-tumor effects in mice. Anticancer Res. 21:2501-2503. -   Matsuo, A., I. Tooyama, S. Isobe, Y. Oomura, I. Akiguchi, K.     Hanai, J. Kimura, and H. Kimura. 1994. Immunohistochemical     localization in the rat brain of an epitope corresponding to the     fibroblast growth factor receptor-1. Neuroscience 60:49-66. -   McCluskie, M. J., R. D. Weeratna, and H. L. Davis. 2000. The role of     CpG in DNA vaccines. Springer Semin. Immunopathol. 22:125-132. -   McNally, M. A., J. S. Lebkowski, T. B. Okarma, and L. B.     Lerch. 1988. Optimizing electroporation parameters for a variety of     human hematopoietic cell lines. Biotechniques 6:882-886. -   Miklavcic, D., K. Beravs, D. Semrov, M. Cemazar, F. Demsar, and G.     Sersa. 1998. The importance of electric field distribution for     effective in vivo electroporation of tissues. Biophys. J     74:2152-2158. -   Mumper, R. J., J. Wang, S. L. Klakamp, H. Nitta, K. Anwer, F.     Tagliaferri, and A. P. Rolland. 1998. Protective interactive     noncondensing (PINC) polymers for enhanced plasmid distribution and     expression in rat skeletal muscle. J. Control Release 52:191-203. -   Muramatsu, T., S. Arakawa, K. Fukazawa, Y. Fujiwara, T. Yoshida, R.     Sasaki, S. Masuda, and H. M. Park. 2001. In vivo gene     electroporation in skeletal muscle with special reference to the     duration of gene expression. Int. J. Mol. Med. 7:3742. -   Nairn, R. S., G. M. Adair, T. Porter, S. L. Pennington, D. G.     Smith, J. H. Wilson, and M. M. Seidman. 1993. Targeting vector     configuration and method of gene transfer influence targeted     correction of the APRT gene in Chinese hamster ovary cells. Somat.     Cell Mol. Genet. 19:363-375. -   Narum, D. L., S. Kumar, W. O. Rogers, S. R. Fuhrmann, H. Liang, M.     Oakley, A. Taye, B. K. Sim, and S. L. Hoffman. 2001. Codon     optimization of gene fragments encoding Plasmodium falciparum     merzoite proteins enhances DNA vaccine protein expression and     immunogenicity in mice. Infect. Immun. 69:7250-7253. -   Neumann, E., M. Schaefer-Ridder, Y. Wang, and P. H.     Hofschneider. 1982. Gene transfer into mouse lyoma cells by     electroporation in high electric fields. EMBO J. 1:841-845. -   Nomoto, S., Y. Tatematsu, T. Takahashi, and H. Osada. 1999. Cloning     and characterization of the alternative promoter regions of the     human LIMK2 gene responsible for alternative transcripts with     tissue-specific expression. Gene 236:259-271. -   Ohlsson, H., S. Thor, and T. Edlund. 1991. Novel insulin promoter-     and enhancer-binding proteins that discriminate between pancreatic     alpha- and beta-cells. Mol. Endocrinol. 5:897-904. -   Otani, Y., Y. Tabata, and Y. Ikada. 1996. Rapidly curable biological     glue composed of gelatin and poly(L-glutamic acid). Biomaterials     17:1387-1391. -   Otani, Y., Y. Tabata, and Y. Ikada. 1998. Hemostatic capability of     rapidly curable glues from gelatin, poly(L-glutamic acid), and     carbodiimide. Biomaterials 19:2091-2098. -   Pech, M., C. D. Rao, K. C. Robbins, and S. A. Aaronson. 1989.     Functional identification of regulatory elements within the promoter     region of platelet-derived growth factor 2. Mol. Cell Biol.     9:396-405. -   Pelletier, J. and N. Sonenberg. 1988. Internal initiation of     translation of eukaryotic mRNA directed by a sequence derived from     poliovirus RNA. Nature 334:320-325. -   Pinkert, C. A., D. M. Omitz, R. L. Brinster, and R. D.     Palmiter. 1987. An albumin enhancer located 10 kb upstream functions     along with its promoter to direct efficient, liver-specific     expression in transgenic mice. Genes Dev. 1:268-276. -   Potter, H., L. Weir, and P. Leder. 1984. Enhancer-dependent     expression of human kappa immunoglobulin genes introduced into mouse     pre-B lymphocytes by electroporation. Proc. Natl. Acad. Sci. U.S. A     81:7161-7165. -   Ross, W., S. E. Aiyar, J. Salomon, and R. L. Gourse. 1998.     Escherichia coli promoters with UP elements of different strengths:     modular structure of bacterial promoters. J. Bacteriol.     180:5375-5383. -   Ryu, D. D. and D. H. Nam. 2000. Recent progress in biomolecular     engineering. Biotechnol. Prog. 16:2-16. -   Scheule, R. K. 2000. The role of CpG motifs in immunostimulation and     gene therapy. Adv. Drug Deliv. Rev. 44:119-134. -   Shi, H., P. S. Yan, C. M. Chen, F. Rahmatpanah, C. Lofton-Day, C. W.     Caldwell, and T. H. Huang. 2002. Expressed CpG island sequence tag     microarray for dual screening of DNA hypermethylation and gene     silencing in cancer cells. Cancer Res. 62:3214-3220. -   Shiraishi, M., A. Sekiguchi, M. J. Terry, A. J. Oates, Y.     Miyamoto, Y. H. Chuu, M. Munakata, and T. Sekiya. 2002. A     comprehensive catalog of CpG islands methylated in human lung     adenocarcinomas for the identification of tumor suppressor genes.     Oncogene 21:3804-3813. -   Skroch, P., C. Buchman, and M. Karin. 1993. Regulation of human and     yeast metallothionein gene transcription by heavy metal ions. Prog.     Clin. Biol. Res. 380:113-28.:113-128. -   Smith, L. C. and J. L. Nordstrom. 2000. Advances in plasmid gene     delivery and expression in skeletal muscle. Curr. Opin. Mol. Ther.     2:150-154. -   Soubrier, F., B. Cameron, B. Manse, S. Somarriba, C. Dubertret, G.     Jaslin, G. Jung, C. L. Caer, D. Dang, J. M. Mouvault, D.     Scherman, J. F. Mayaux, and J. Crouzet. 1999. pCOR: a new design of     plasmid vectors for nonviral gene therapy. Gene Ther. 6:1482-1488. -   Stanford, W. L., J. B. Cohn, and S. P. Cordes. 2001. Gene-trap     mutagenesis: past, present and beyond. Nat. Rev. Genet. 2:756-768. -   Terada, Y., H. Tanaka, T. Okado, S. Inoshita, M. Kuwahara, T.     Akiba, S. Sasaki, and F. Marumo. 2001. Efficient and     ligand-dependent regulated erythropoietin production by naked dna     injection and in vivo electroporation. Am. J. Kidney Dis.     38:S50-S53. -   Tollefsen, S., M. Vordermeier, I. Olsen, A. K. Storset, L. J.     Reitan, D. Clifford, D. B. Lowrie, H. G. Wiker, K. Huygen, G.     Hewinson, I. Mathiesen, and T. E. Tjelle. 2003. DNA injection in     combination with electroporation: a novel method for vaccination of     farmed ruminants. Scand. J. Immunol. 57:229-238. -   Tone, C. M., D. M. Cardoza, R. H. Carpenter, and R.     Draghia-Akli. 2004. Long-term effects of plasmid-mediated growth     hormone releasing hormone in dogs. Cancer Gene Ther. 11:389-396. -   Toneguzzo, F., A. Keating, S. Glynn, and K. McDonald. 1988. Electric     field-mediated gene transfer: characterization of DNA transfer and     patterns of integration in lymphoid cells. Nucleic Acids Res.     16:5515-5532. -   Tripathy, S. K., E. C. Svensson, H. B. Black, E. Goldwasser, M.     Margalith, Hobart, P M, and J. M. Leiden. 1996. Long-term expression     of erythropoietin in the systemic circulation of mice after     intramuscular injection of a plasmid DNA vector. Proc. Natl. Acad.     Sci. USA 93:10876-10880. -   Tronche, F., A. Rollier, I. Bach, M. C. Weiss, and M. Yaniv. 1989.     The rat albumin promoter: cooperation with upstream elements is     required when binding of APF/HNF1 to the proximal element is     partially impaired by mutation or bacterial methylation. Mol. Cell     Biol. 9:4759-4766. -   Tronche, F., A. Rollier, P. Herbomel, I. Bach, S. Cereghini, M.     Weiss, and M. Yaniv. 1990. Anatomy of the rat albumin promoter. Mol.     Biol. Med. 7:173-185. -   Trudel, M. and F. Costantini. 1987. A 3′ enhancer contributes to the     stage-specific expression of the human beta-globin gene. Genes Dev.     1:954-961. -   Tsumaki, N., T. Kimura, K. Tanaka, J. H. Kimura, T. Ochi, and Y.     Yamada. 1998. Modular arrangement of cartilage- and neural     tissue-specific cis-elements in the mouse alpha2(XI) collagen     promoter. J. Biol. Chem. 273:22861-22864. -   Tsurumi, Y., S. Takeshita, D. Chen, M. Kearney, S. T. Rossow, J.     Passeri, J. R. Horowitz, J. F. Symes, and J. M. Isner. 1996. Direct     intramuscular gene transfer of naked DNA encoding vascular     endothelial growth factor augments collateral development and tissue     perfusion [see comments]. Circulation 94:3281-3290. -   Tur-Kaspa, R., L. Teicher, B. J. Levine, A. I. Skoultchi, and D. A.     Shafritz. 1986. Use of electroporation to introduce biologically     active foreign genes into primary rat hepatocytes. Mol. Cell Biol.     6:716-718. -   Vilquin, J. T., P. F. Kennel, M. Patumeau-Jouas, P. Chapdelaine, N.     Boissel, P. Delaere, J. P. Tremblay, D. Scherman, M. Y. Fiszman,     and K. Schwartz. 2001. Electrotransfer of naked DNA in the skeletal     muscles of animal models of muscular dystrophies. Gene Ther.     8:1097-1107. -   Wolff, J. A., R. W. Malone, P. Williams, W. Chong, G. Acsadi, A.     Jani, Felgner, and P L. 1990. Direct gene transfer into mouse muscle     in vivo. Science 247:1465-1468. -   Wu, H. K., J. A. Squire, Q. Song, and R. Weksberg. 1997.     Promoter-dependent tissue-specific expressive nature of imprinting     gene, insulin-like growth factor II, in human tissues. Biochem.     Biophys. Res. Commun. 233:221-226. -   Xie, T. D. and T. Y. Tsong. 1993. Study of mechanisms of electric     field-induced DNA transfection. V. Effects of DNA topology on     surface binding, cell uptake, expression, and integration into host     chromosomes of DNA in the mammalian cell. Biophys. J. 65:1684-1689. -   Yasui, A., K. Oda, H. Usunomiya, K. Kakudo, T. Suzuki, T.     Yoshida, H. M. Park, K. Fukazawa, and T. Muramatsu. 2001. Elevated     gastrin secretion by in vivo gene electroporation in skeletal     muscle. Int. J Mol. Med. 8:489-494. -   Yin, D. and J. G. Tang. 2001. Gene therapy for     streptozotocin-induced diabetic mice by electroporational transfer     of naked human insulin precursor DNA into skeletal muscle in vivo.     FEBS Lett. 495:16-20. -   Yorifuji, T. and H. Mikawa. 1990. Co-transfer of restriction     endonucleases and plasmid DNA into mammalian cells by     electroporation: effects on stable transformation. Mutat. Res.     243:121-126. -   Yutzey, K. E. and S. F. Konieczny. 1992. Different E-box regulatory     sequences are functionally distinct when placed within the context     of the troponin I enhancer. Nucleic Acids Res. 20:5105-5113. -   Zhao-Emonet, J. C., O. Boyer, J. L. Cohen, and D. Klatzmann. 1998.     Deletional and mutational analyses of the human CD4 gene promoter:     characterization of a minimal tissue-specific promoter. Biochim.     Biophys. Acta 1442:109-119. -   Zheng, Q. and D. J. Kyle. 1996. Computational screening of     combinatorial libraries. Bioorg. Med. Chem. 4:631-638. -   Zuker, M. 2003. Mfold web server for nucleic acid folding and     hybridization prediction. Nucleic Acids Res. 31:3406-3415. -   The Eukaryotic Promoter Data Base EPDB, http://www.epd.isb-sib.ch/ 

1. A synthetic mammalian expression plasmid comprising: (a) a synthetic or eukaryotic promoter; (b) a codon-optimized-eukaryotic therapeutic gene sequence; (c) a poly adenylation signal; (d) a selectable marker gene promoter; (e) a ribosomal binding site; (f) an origin of replication comprising a sequence that is at least 95% identical to SEQ ID No.:
 42. wherein the synthetic or eukaryotic promoter, the codon-optimized-eukaryotic therapeutic gene sequence, and the polyadenylation signal comprise therapeutic elements of the synthetic mammalian expression plasmid; the therapeutic elements are operatively linked and located in a first operatively-linked arrangement; the selectable marker gene promoter, the ribosomal binding site, the codon-optimized selectable marker gene sequence, and the origin of replication comprise replication elements of the synthetic mammalian expression plasmid; the replication elements are operatively linked and located in a second operatively-linked arrangement; and the first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the synthetic mammalian expression plasmid.
 2. The synthetic mammalian expression plasmid of claim 1, wherein the origin of replication comprises SEQ ID No.:
 39. 3. The synthetic mammalian expression plasmid of claim 1, wherein the origin of replication comprises SEQ ID No.:
 40. 4. The synthetic mammalian expression plasmid of claim 1, wherein the origin of replication comprises SEQ ID No.:
 41. 5. The synthetic mammalian expression plasmid of claim 1, wherein the poly adenylation signal (“PolyA”) comprises SEQ ID NO.:
 10. 6. The synthetic mammalian expression plasmid of claim 1, further comprising a prokaryotic promoter.
 7. The synthetic mammalian expression plasmid of claim 1, wherein the codon-optimized-eukaryotic therapeutic gene sequence encodes a species-specific signal peptide.
 8. The synthetic mammalian expression plasmid of claim 1, wherein the codon-optimized-eukaryotic therapeutic gene sequence comprises a sequence that encodes a species-specific or modified growth hormone releasing hormone (“GHRH”).
 9. The synthetic mammalian expression plasmid of claim 8, wherein the modified growth hormone releasing hormone (“GHRH”) comprises a sequence that is at least 90% identical to SEQ ID No.:
 30. 10. The synthetic mammalian expression plasmid of claim 9, wherein the modified growth hormone releasing hormone (“GHRH”) is: SEQ ID No.: 17; SEQ ID No.: 18; SEQ ID No.: 19; SEQ ID No.: 20; SEQ ID No.: 21; SEQ ID No.: 22; SEQ ID No.: 23; SEQ ID No.: 24; SEQ ID No.: 25; SEQ ID No.: 26; SEQ ID No.: 27; SEQ ID No.: 28 or SEQ ID No.:
 29. 11. The synthetic mammalian expression plasmid of claim 1, further comprising a 5′ untranslated region (“5′UTR”) operatively linked to the first operatively-linked arrangement.
 12. The synthetic mammalian expression plasmid of claim 11, wherein the 5′ untranslated region (“5′UTR”) comprises a portion of a human growth hormone 5′UTR.
 13. The synthetic mammalian expression plasmid of claim 1, wherein the codon-optimized-eukaryotic therapeutic gene sequence comprises a sequence that is at least 90% identical to SEQ ID NO.:
 6. 14. The synthetic mammalian expression plasmid of claim 13, wherein the codon-optimized-eukaryotic therapeutic gene sequence is SEQ ID NO.: 4; SEQ ID NO.: 7; SEQ ID NO.: 8; SEQ ID NO.: 9; or SEQ ID NO.:
 10. 15. A method for plasmid mediated gene supplementation comprising: delivering into cells of a subject a codon-optimized high yield synthetic mammalian expression plasmid; wherein the codon-optimized high yield synthetic mammalian expression plasmid encodes a growth hormone releasing hormone (“GHRH”) and contains at least an origin of replication sequence comprising a sequence that is at least 95% identical to SeqID No.:42.
 16. The method of claim 15, wherein delivering into the cells of the subject the codon-optimized high yield synthetic mammalian expression plasmid is via electroporation.
 17. The method of claim 15, wherein the cells of the subject are somatic cells, stem cells, or germ cells.
 18. The method of claim 15, wherein the codon-optimized high yield synthetic mammalian expression plasmid consisting of SEQ ID NO.: 12, SEQ ID NO.: 13, SEQ ID NO.: 14, SEQ ID NO.: 15, SEQ ID NO.: 33 and SEQ ID NO.:
 34. 19. The method of claim 15 wherein the encoded GHRH facilitates growth hormone (“GH”) secretion in the subject.
 20. An isolated nucleic acid having an origin of replication comprising a sequence that is at least 95% identical to SEQ ID No.:
 42. 21. The isolated nucleic acid of claim 20, wherein the origin of replication comprises SEQ ID No.:
 39. 22. The isolated nucleic acid of claim 20, wherein the origin of replication comprises SEQ ID No.:
 40. 23. The isolated nucleic acid of claim 20, wherein the origin of replication comprises SEQ ID No.:
 41. 24. An isolated nucleic acid comprising a sequence that is at least 95% identical to SEQ ID No.: 31, SEQ ID No.: 32, SEQ ID No.: 33, SEQ ID No.: 34, SEQ ID No.: 35, or SEQ ID No.:
 15. 